WO2014115229A1 - 抗体結合性ペプチド - Google Patents
抗体結合性ペプチド Download PDFInfo
- Publication number
- WO2014115229A1 WO2014115229A1 PCT/JP2013/007583 JP2013007583W WO2014115229A1 WO 2014115229 A1 WO2014115229 A1 WO 2014115229A1 JP 2013007583 W JP2013007583 W JP 2013007583W WO 2014115229 A1 WO2014115229 A1 WO 2014115229A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- polypeptide
- amino acid
- protein
- region
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 455
- 230000027455 binding Effects 0.000 title claims abstract description 319
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 332
- 229920001184 polypeptide Polymers 0.000 claims abstract description 320
- 229940027941 immunoglobulin g Drugs 0.000 claims abstract description 317
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 144
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 116
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 116
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims description 117
- 102000037865 fusion proteins Human genes 0.000 claims description 88
- 108020001507 fusion proteins Proteins 0.000 claims description 88
- 241000700605 Viruses Species 0.000 claims description 28
- 108010058683 Immobilized Proteins Proteins 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 17
- 150000002894 organic compounds Chemical class 0.000 claims description 12
- 229910010272 inorganic material Inorganic materials 0.000 claims description 11
- 150000002484 inorganic compounds Chemical class 0.000 claims description 10
- 239000007790 solid phase Substances 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108091005573 modified proteins Proteins 0.000 claims description 3
- 102000035118 modified proteins Human genes 0.000 claims description 3
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 24
- 238000001514 detection method Methods 0.000 abstract description 18
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 85
- 108020004414 DNA Proteins 0.000 description 60
- 102000002933 Thioredoxin Human genes 0.000 description 57
- 108060008226 thioredoxin Proteins 0.000 description 57
- 229940094937 thioredoxin Drugs 0.000 description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 42
- 239000000872 buffer Substances 0.000 description 37
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 35
- 239000000523 sample Substances 0.000 description 30
- 238000005259 measurement Methods 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000001042 affinity chromatography Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 17
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 239000004365 Protease Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000010494 dissociation reaction Methods 0.000 description 13
- 230000005593 dissociations Effects 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000010306 acid treatment Methods 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 108090000526 Papain Proteins 0.000 description 9
- 229940125644 antibody drug Drugs 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 229940055729 papain Drugs 0.000 description 9
- 235000019834 papain Nutrition 0.000 description 9
- 108010069514 Cyclic Peptides Proteins 0.000 description 8
- 102000001189 Cyclic Peptides Human genes 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 238000002823 phage display Methods 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 108010067902 Peptide Library Proteins 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000005291 magnetic effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000004850 protein–protein interaction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 4
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 241000724791 Filamentous phage Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940099472 immunoglobulin a Drugs 0.000 description 4
- 238000007885 magnetic separation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960003151 mercaptamine Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000002344 surface layer Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000028555 IgG binding proteins Human genes 0.000 description 3
- 108091009325 IgG binding proteins Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 239000012515 MabSelect SuRe Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101800000936 Structural peptide 4 Proteins 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 238000011481 absorbance measurement Methods 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- -1 dextran and agarose Chemical class 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002875 fluorescence polarization Methods 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003380 quartz crystal microbalance Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102220603202 DNA polymerase delta subunit 4_R17A_mutation Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102220625795 Sulfotransferase 2B1_I20A_mutation Human genes 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 2
- 102220586108 Tubulin polymerization-promoting protein_S18A_mutation Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 102200095678 rs11004439 Human genes 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- XNSKSTRGQIPTSE-ACZMJKKPSA-N Arg-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O XNSKSTRGQIPTSE-ACZMJKKPSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100020780 DNA polymerase delta subunit 4 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 101100494726 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pep-4 gene Proteins 0.000 description 1
- XCCHFTFMUQWCPL-GXQDVZPWSA-N ON1C(CCC1=O)=O.C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)C(C(=O)O)CCCCN Chemical compound ON1C(CCC1=O)=O.C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)C(C(=O)O)CCCCN XCCHFTFMUQWCPL-GXQDVZPWSA-N 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229940045950 pep-20 Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 102200038092 rs6759892 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 101150099695 vps11 gene Proteins 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Definitions
- the present invention relates to a peptide showing binding activity to the Fc region of immunoglobulin G, and an antibody, immunoglobulin G or protein containing the immunoglobulin G Fc region, and a method for detecting, purifying, immobilizing or removing the same.
- the so-called antibody drug which uses monoclonal antibodies for therapeutic purposes, is the largest biopharmaceutical segment with annual sales exceeding $ 30 billion, and the fastest growing segment of the entire pharmaceutical industry. To date, 23 full-size monoclonal antibodies and three fragmented monoclonal antibodies have been launched, some of which are already blockbusters with annual sales of over $ 1 billion. The number of monoclonal antibodies as drug candidates for which clinical trials were started between 1995 and 2007 has increased more than three times, and the number continues to grow (Non-patent Document 1).
- Non-patent Document 2 Non-patent Document 2
- Suzuki et al. Identified multiple polypeptides having binding activity to the Fc region of human IgG using a phage library displaying 7- or 12-residue linear peptides on filamentous bacteriophage M13, and bound to the Fc region. The presence or absence of sex was measured by enzyme-linked immunosorbent assay (ELISA) (Patent Document 1). In addition to binding to human IgG, they created peptides by extracting common sequences from the identified sequences, as well as IgG Fc from horses, sheep, rabbits, guinea pigs, goats, cats, dogs, cows, pigs, and mice. Binding activity to the region was confirmed by ELISA.
- ELISA enzyme-linked immunosorbent assay
- Verdoliva et al. Screened a synthetic peptide library represented by (Cys Xaa 3 ) 2 Lys Gly (SEQ ID NO: 167) introduced with a branched structure with Lys residues and cyclization with Cys residues against mouse monoclonal IgG, A peptide FcRM showing binding properties in the vicinity of the hinge region was prepared. They further constructed affinity chromatography with this FcRM immobilized, and reported purification of mouse and human IgG (Non-patent Document 9).
- Non-patent Document 10 Used a phage library displaying a cyclic peptide represented by Cys Xaa 7-10 Cys on a T7 bacteriophage to produce a peptide that binds to the Fc region of human IgG (Non-patent Document 10).
- the peptides produced by them differ from the above-mentioned IgG-binding peptides produced so far in that they recognize not the natural structure of the Fc region but the non-natural structure produced by acid treatment. Ito et al. Disclosed that this peptide can be used to investigate the content of non-natural structure produced by acid treatment in human antibody drugs, immunoglobulin preparations, and IgG reagents (Patent Document 3).
- an antibody-binding molecule that has appropriate characteristics in terms of whether it binds to an antibody of an animal species or only to an antibody of a specific animal species, whether it is soluble or stable, and can be mass-produced. is there. Furthermore, in the case of peptides, whether it contains non-natural amino acid residues or only natural amino acid residues, the chemical structure is linear, cyclic or branched, and has a three-dimensional structure that is stable in solution. Whether it is formed or can be used in a reducing environment is also an item of aptitude judgment.
- short-chain polypeptides are improved in functionality by cyclic stabilization such as intramolecular disulfide bridges, but the cyclization requires complicated chemical reactions, and for example, formation of disulfide bridges under reducing conditions, etc. Under difficult conditions, the binding function cannot be exhibited. Examples of situations where disulfide bridge formation is difficult are as follows: (1) cytoplasmic environment, and (2) thiol groups of cysteine residues in the target IgG or Fc region are released for the purpose of chemical modification, etc. An environment where a reducing agent is added to make a base is assumed.
- Non-patent document 11 It has been reported that antibody molecules form a non-natural structure called an alternative folded state (AFS) different from a normal natural structure due to various physical or chemical stresses. Such a non-natural structure has been suggested to have a risk of causing a side effect due to the induction of immunogenicity as well as a decrease in the effect of the drug, and a technique for analyzing an antibody having a non-natural structure is required. (Non-patent document 12).
- AFS alternative folded state
- Analysis techniques that can clarify the molecular shape or three-dimensional structure of proteins include X-ray crystal structure analysis, nuclear magnetic resonance, electron microscope, analytical ultracentrifugation, isoelectric focusing, dynamic light scattering, circular polarization
- X-ray crystal structure analysis and nuclear magnetic resonance capable of providing three-dimensional structure information with atomic level accuracy require analysis time on the order of several months.
- dynamic light scattering or liquid chromatography which can complete the measurement in a few minutes, cannot detect minute changes in molecules or minute amounts of contamination. For this reason, a simple technique that achieves both atomic level accuracy and throughput is required.
- Non-patent Document 13 an affinity chromatography technique using a molecule having a specific affinity for an antibody as a ligand is indispensable today.
- natural proteins derived from bacteria such as protein A and protein G are used as ligands for this purpose. These proteins have good antibody affinity, but have disadvantages of low stability and high production costs.
- JP 2004-187563 A International Publication Number WO / 2001/045746 Specification International Publication Number WO / 2008/054030 Specification
- the present invention has binding activity to the Fc region of immunoglobulin G, and can be suitably used for detection, purification, immobilization, or removal of an antibody, immunoglobulin G, or a protein containing the Fc region of immunoglobulin G.
- the purpose is to provide new polypeptides and to expand the molecular diversity of antibody-binding polypeptides available in the industry.
- a short polypeptide having a specific amino acid sequence pattern exhibits high binding activity to a human IgG antibody. Furthermore, it was also shown that these polypeptides have a low dissociation rate in binding to a human IgG antibody, and that the binding is more easily retained. Furthermore, it was shown that some of these polypeptides bind only to the non-natural structure of human IgG antibody obtained by acid treatment and reduction treatment. The present invention has been completed based on these findings.
- the terms “peptide”, “polypeptide” and “protein” are used interchangeably.
- the present invention includes the following.
- Formula 1 YDPxTGTWRSx- [IL] (SEQ ID NO: 1) (1)
- x represents any amino acid residue.
- [] Represents any one of the amino acid residues in [].
- a polypeptide consisting of an amino acid sequence to which one or several amino acid residues are added in the amino acid sequence, and binding activity to the Fc region of immunoglobulin G
- a polypeptide showing: [2] SEQ ID NOs: 2 to 6: YDPRTGTWRSSIAYGGG (SEQ ID NO: 2) YDPGTGTWRSYLRFGGG (SEQ ID NO: 3) YDPYTGTWRSSIWVLSG (SEQ ID NO: 4) YDPGTGTWRSWLSFNVG (SEQ ID NO: 5) YDPWTGTWRSFIWGGGG (SEQ ID NO: 6)
- the polypeptide according to [1] comprising the amino acid sequence represented by any of the following: [3]
- [] Represents any one of the amino acid residues in [].) Or a polypeptide consisting of an amino acid sequence to which one or several amino acid residues are added in the amino acid sequence, and binding activity to the Fc region of immunoglobulin G
- polypeptide according to [20] which is a linked polypeptide obtained by extending two polypeptides; [22] Amino terminus or carboxyl of the polypeptide of any one of [1], [3], [5], [7], [9], [12], [14], [16], and [18] A fusion protein in which a protein is bound to one end or both ends, and shows a binding activity to the Fc region of immunoglobulin G; [23] Proteins at the amino terminus, carboxyl terminus, or both terminus of the polypeptide of any of SEQ ID NOs: 2-9, 11-19, 21, 22, 24-55, 57-81, 158-164, and 174-178 A protein according to [22], which is a fusion protein bound with [24] The protein according to [22], comprising the amino acid sequence represented by any of SEQ ID NOs: 82 to 119; [25] A nucleic acid encoding the polypeptide or protein according to any one of [1] to [24]; [26] The nucle
- the antibody, immunoglobulin G or Fc region-containing protein having a non-natural three-dimensional structure is brought into contact with the immobilized polypeptide or immobilized protein described in the above, and the polypeptide, protein, transformant, recombinant phage or group Binding to a recombinant virus, or an immobilized polypeptide or protein, and (2) A polypeptide, protein, transformant, recombinant phage or recombinant virus, or an antibody having an unnatural three-dimensional structure bound to an immobilized polypeptide or immobilized protein, an immunoglobulin G or Fc region-containing protein Recovering from the sample,
- a method comprising: [36] A method for removing an antibody having an unnatural three-dimensional structure, an immunoglobulin G or an Fc region-containing protein, (1) The poly
- the antibody, immunoglobulin G or Fc region-containing protein having a non-natural three-dimensional structure is brought into contact with the immobilized polypeptide or immobilized protein described in the above, and the polypeptide, protein, transformant, recombinant phage or group Binding to a recombinant virus, or an immobilized polypeptide or protein, and (2) A polypeptide, protein, transformant, recombinant phage or recombinant virus, or an antibody having an unnatural three-dimensional structure bound to an immobilized polypeptide or immobilized protein, an immunoglobulin G or Fc region-containing protein Removing from the sample,
- a method comprising: [37] The method according to any one of [34] to [36], which is carried out in a reducing environment.
- the polypeptide of the present invention exhibits high binding activity to human IgG antibody and has a slow dissociation rate in binding to human IgG antibody. Furthermore, some of these polypeptides bind only to the non-natural structure of the human IgG antibody obtained by acid treatment and reduction treatment, and do not bind to the natural IgG antibody.
- the IgG-binding polypeptide of the present invention can be used to immobilize, detect, purify, and remove antibody immunoglobulin G (IgG) or a fusion protein to which the Fc region has been added.
- Polypeptide 2A1 (SEQ ID NO: 11) ⁇ ⁇ ⁇ having SEQ ID NO: 10 as a common amino acid sequence does not show any binding to natural IgG, unlike normal IgG-binding molecules, and is not caused by acid treatment, reduction treatment, etc. It binds specifically to the native structure. This property can be used for immobilization, detection, purification, and removal of IgG having a non-natural structure.
- polypeptide 2A1 also exhibits binding activity to the Fc region exposed to reducing conditions.
- polypeptide 2A1 exhibits high heat inactivation resistance.
- the IgG-binding polypeptide of the present invention does not depend on stabilization by cyclization, it does not require a complicated chemical reaction accompanying cyclization, and for example, conditions under which disulfide bridge formation is difficult such as under reducing conditions. Even below, the binding function can be expressed.
- (A) shows the results of measurement of binding activity to the 2A1 human Fc region (Jackson Immunoresearch) by surface plasmon resonance. Represents the binding curve of each human Fc region diluted to a concentration of 600, 500, 400, 300, 200, 100 nM for 2A1 immobilized on the sensor chip.
- (B) shows the results of measuring the binding activity of 2A1 against natural human monoclonal IgG by surface plasmon resonance. Represents the binding curve of each natural IgG diluted to a concentration of 600, 500, 400, 300, 200, 100 nM for 2A1 immobilized on the sensor chip.
- (C) shows the results of measuring the binding activity of 2A1 against the natural human Fc region by surface plasmon resonance.
- D shows the results of measuring the binding activity of 2A1 to acid-denatured human IgG by surface plasmon resonance. The binding curve of each acid-denatured human IgG diluted to a concentration of 250, 125 nM to 2A1 immobilized on the sensor chip is shown.
- (E) shows the results of measuring the binding activity of 2A1 to the reduced human Fc region by surface plasmon resonance. Represents the binding curve of each reduced human Fc region diluted to a concentration of 600, 400, or 200 nM for 2A1 immobilized on the sensor chip.
- (F) shows the results of measurement of binding activity to 2A1 AFS-type human IgG by surface plasmon resonance.
- the detection result of mixed AFS type IgG by surface plasmon resonance is shown. It represents a binding curve for a sample in which AFS-type IgG was mixed at a ratio of 10, 5, 1, 0.1, 0.01, 0.001% to a natural IgG of a concentration of 6.7 ⁇ M.
- the detection result of mixed AFS type IgG by size exclusion chromatography is shown.
- a chromatogram for a sample in which AFS type IgG is mixed at a ratio of 10, 5, 1, 0.1, 0.01, 0.001% to a natural type IgG with a concentration of 6.7 M is shown.
- the inset shows an enlarged version of the multimeric fraction.
- B The result regarding the detection range of AFS type IgG by size exclusion chromatography is shown. Calculate the abundance of the multimeric fraction based on the peak areas of the multimeric and monomeric fractions of IgG obtained from the chromatogram in Fig.
- the results of electrophoresis of the molecular weight marker (lane 1), the flow-through fraction (lane 2), the elution fraction (lane 3), and the column (lane 4) in the chromatogram of FIG. 5 are shown.
- purification by affinity chromatography of human IgG using a p17_trx fixed column is shown.
- the solid line shows a chromatogram obtained by applying human monoclonal IgG to a column and eluting with a pH gradient. The broken line indicates the pH of the buffer. Evaluation of binding specificity using 2A1 peptide-immobilized resin.
- the present invention relates to a polypeptide showing binding activity to immunoglobulin G and its Fc region, and a method for detecting, fixing, purifying or removing immunoglobulin G and Fc region using the same.
- amino acid sequence of the polypeptide of the present invention is YDPxTGTWRSx- [IL] represented by SEQ ID NO: 1 (wherein x represents any amino acid residue. [] Is an amino acid within [ ⁇ ]. Which represents any one of the residues) as a consensus sequence. More preferably, it is a polypeptide comprising the amino acid sequence shown in SEQ ID NOs: 2 to 6. Like the polypeptides represented by SEQ ID NOs: 7 to 9 shown in Example 1 below, the polypeptide of the present invention has binding activity to the Fc region of immunoglobulin G based on this common sequence ⁇ ⁇ (SEQ ID NO: 1).
- a polypeptide comprising an amino acid sequence in which several, for example, 1 to 6, preferably 1 to 3, more preferably 1 or 2 amino acid residues are added, deleted, substituted or inserted as long as they are not impaired. Including. The number of amino acid residues in the polypeptide sequence is not limited as long as it includes the above amino acid sequence.
- the recombinant phage displaying the polypeptide on the surface layer by transforming with the nucleic acid encoding the polypeptide also has binding activity to the Fc region of immunoglobulin G.
- this invention includes the transformant which has the nucleic acid which codes the polypeptide which has the said amino acid sequence, the fusion protein containing this, and these polypeptides or fusion protein.
- R- [QRS] -xx- [GS] -YDPRTGTWRSSIAYGG represented by SEQ ID NO: 10 (wherein x represents any amino acid residue. [] Is within [].
- a polypeptide comprising a consensus sequence as a consensus sequence more preferably a polypeptide comprising the amino acid sequence represented by SEQ ID NOs: 11 to 14.
- SEQ ID NOS: 15 to 21 shown in Example 1 below the polypeptide of the present invention loses the binding activity to the Fc region of immunoglobulin G based on this common sequence (SEQ ID NO: 10).
- a polypeptide comprising an amino acid sequence in which several, for example, 1 to 10, preferably 1 to 6, more preferably 1 to 3 amino acid residues are added, deleted, substituted or inserted is included.
- the number of amino acid residues in the polypeptide sequence is not limited as long as it includes the above amino acid sequence.
- a polypeptide comprising DAAWHLGELVWATYYDPETGT-WxPDWxxM (wherein x represents any amino acid residue) represented by SEQ ID NO: 23 as a common sequence, more preferably SEQ ID NO: 24-54
- a polypeptide comprising the amino acid sequence represented by Like the polypeptide represented by the amino acid sequence of SEQ ID NO: 55 shown in Example 2 below, the polypeptide of the present invention has binding activity to the Fc region of immunoglobulin G based on this common sequence (SEQ ID NO: 23).
- a polypeptide consisting of an amino acid sequence in which several, for example, 1 to 10, preferably 1 to 6, more preferably 1 to 3 amino acid residues are added, deleted, substituted or inserted as long as they are not damaged .
- the number of amino acid residues in the polypeptide sequence is not limited as long as it includes the above amino acid sequence.
- [RSG]-[AGV] -xYDPETGTWYDAAWHLGELVW-ATYYDPETGTWEPDWQRMLGQ (wherein x represents any amino acid residue. [] Represents the amino acid residue in [].
- the polypeptide of the present invention binds to the Fc region of immunoglobulin G based on this common sequence (SEQ ID NO: 56).
- a polypeptide comprising an amino acid sequence in which several, for example, 1 to 10, preferably 1 to 6, more preferably 1 to 3 amino acid residues are added, deleted, substituted or inserted within a range in which the activity is not impaired including.
- the number of amino acid residues in the polypeptide sequence is not limited as long as it includes the above amino acid sequence.
- the polypeptide and protein of the present invention may be labeled. That is, the present invention provides a modified poly- mer in which an organic compound, an inorganic compound, or both an organic compound and an inorganic compound are bound to the above-mentioned polypeptide or fusion protein as long as the binding activity to the Fc region of immunoglobulin G is not impaired. Includes peptides or modified proteins. By binding the above organic compound, etc., it is possible to effectively immobilize, purify, detect, and remove antibodies, immunoglobulin G or proteins containing the Fc region of immunoglobulin G, which are examples of uses of the present invention described in the lower part. It can be carried out.
- organic compounds used include fluorescent organic compounds such as biotin and fluorescein, stable isotopes, phosphate groups, acyl groups, amide groups, ester groups, epoxy groups, polyethylene glycol (PEG), lipids, sugar chains, nucleic acids, Fluorescent inorganic compounds such as quantum dots and gold colloids are preferred (Basle E, Joubert N, Pucheault M. Protein chemical modification on endogenous amino acids. Chem Biol. 2010, 17 (3), 213-27.) Does not exclude any other technically applicable compounds.
- fluorescent organic compounds such as biotin and fluorescein, stable isotopes, phosphate groups, acyl groups, amide groups, ester groups, epoxy groups, polyethylene glycol (PEG), lipids, sugar chains, nucleic acids, Fluorescent inorganic compounds such as quantum dots and gold colloids are preferred (Basle E, Joubert N, Pucheault M. Protein chemical modification on endogenous amino acids. Chem Biol. 2010, 17 (3), 213-27.) Does not exclude
- the use of the polypeptide of the present invention is not limited as long as it uses the binding activity to the Fc region of immunoglobulin G of the molecule.
- immobilization and purification of antibodies, immunoglobulin G, or proteins containing the Fc region of immunoglobulin G are used for artificially produced immunoglobulin G binding polypeptides or microorganism-derived immunoglobulin G binding proteins.
- detection and removal There is detection and removal (Non-patent document 14, Non-patent document 15, Patent document 1, Patent document 3, Non-patent document 6, Non-patent document 9). Therefore, uses of the polypeptide of the present invention include all forms that are technically applicable among uses known to those skilled in the art, including uses carried out using the immunoglobulin G-binding molecule. In the examples described later, detection, purification, and removal of immunoglobulin G are mentioned, but other forms of use are not excluded.
- a polypeptide having SEQ ID NO: 10 as a common amino acid sequence has specific binding activity to immunoglobulin G and Fc regions having a non-natural structure as shown in Example 1 7) below. Therefore, it can be used for immobilization, purification, detection and removal of immunoglobulin G and Fc regions of non-natural structure.
- a non-natural structure is a general term for a structure group different from a natural structure, which is caused by a physical impact such as acid treatment, heat treatment, modifier treatment, reducing agent treatment, shearing or stirring. is there.
- the acid treatment is not limited, but preferably means exposure to pH 4.0 or lower, more preferably pH 1.5 to 2.0.
- immunoglobulin G forms a non-natural structure called Alternative folded state (AFS), which is different from the normal natural structure, by treating with 10 mM Glycine-HCl, 150 mM NaCl, pH 2.0 buffer. It has been reported (Non-patent document 16, Non-patent document 17, Non-patent document 18).
- Non-patent Document 19 As other chemical treatments and physical treatments, physical impacts such as reducing agent treatment, shearing and stirring are widely known.
- reducing agent treatment refers to a state where the intramolecular or intermolecular disulfide bond is partially or entirely cleaved.
- Non-patent document 21 refers to the state in which the disulfide bond is cleaved by the addition of a reducing agent (DTT, ⁇ -mercaptoethanol, 2-mercaptoethylamine, etc.).
- a reducing agent DTT, ⁇ -mercaptoethanol, 2-mercaptoethylamine, etc.
- the reduction treatment was performed by treating with 50 mM mM 2-mercaptoethylamine for 90 minutes, but the reagent causing the reduction conditions is not limited thereto.
- the physical impact such as stirring and shearing is not limited, but for example, by rotating an immunoglobulin G solution at a speed of 700 rpm using a stirring bar, oxidation of amino acid residues, It has been reported that denaturation and resulting protein aggregation occur (Non-patent document 21, Non-patent document 22).
- Example 1 the results of the measurement of the binding activity to the immunoglobulin G and Fc regions treated with acid and / or heat treatment, reduction treatment, AFS formation conditions with acid are shown.
- immunoglobulin G and Fc regions bound by the peptide other non-natural structures are not excluded.
- the immunoglobulin G-binding polypeptide of the present invention does not depend on cyclization by disulfide bridge, and functionalization / stabilization thereby. Accordingly, the binding function can be expressed even under reducing conditions in which formation of disulfide bridges is difficult. Examples of situations where reduction conditions that make disulfide bridge formation difficult are assumed include (1) cytoplasmic environment, (2) thiol group of cysteine residues in the target immunoglobulin G or Fc region, etc. For example, an environment in which a reducing agent is added to form a free radical is assumed.
- Example 1 the Fc region was treated with reducing agent 2-mercaptoethylamine (Thermo Scientific Pierce) ⁇ ⁇ as the reducing condition, and the reducing condition was maintained in the presence of the chelating agent ethylenediaminetetraacetic acid (non- However, other disulfide non-crosslinking conditions are not excluded.
- reducing agent 2-mercaptoethylamine Thermo Scientific Pierce
- the method for synthesizing the polypeptide and the form to be used are not limited.
- the methods for preparing the identified polypeptide include organic chemical synthesis and genetic recombination methods (Reference: Kenji Samukawa, Peptide and Drug Discovery, Medical Do), and expression in the form of a fusion protein linked to any protein. Numerous synthetic methods have been reported, such as Method IV (reference: Tatsuya Moriyama, Tips for Protein Purification and Handling, Yodosha), and preparation of polypeptides with specified amino acid sequences can be easily performed by applying existing synthesis techniques. Can do.
- preparation by organic chemical synthesis preparation by cell expression as a fusion protein
- preparation of the target polypeptide by protease cleavage of the fusion protein preparation of the target polypeptide by protease cleavage of the fusion protein
- transformation with a nucleic acid encoding the polypeptide An example of a recombinant phage displaying the polypeptide on the surface is shown, but other methods including the above techniques are not excluded.
- the present invention also relates to a solid phase carrier on which the polypeptide of the present invention is immobilized.
- suitable solid phase carriers include, but are not limited to, resins such as polystyrene and polyester, biopolymer compounds such as dextran and agarose, and inorganic materials such as metal and glass.
- the shape of these solid phase carriers may be any shape such as particles, plates, membranes, chips, and test tubes.
- the immobilization method of the polypeptide to these solid phase carriers can be performed by a covalent bond method, a physical adsorption method, an ion bond method, or an intermolecular interaction method.
- the surface plasmon resonance measuring device is immobilized on the sensor chip by the covalent bond method, and is immobilized on the polymer particles as the affinity chromatography column.
- other support carriers are used. Does not exclude immobilization methods.
- a molecule containing the polypeptide, such as the polypeptide of the present invention and a fusion protein, can be suitably used for immobilizing, purifying, or removing the immunoglobulin G and Fc regions by immobilizing it on a solid phase carrier.
- Fab G was purified by affinity chromatography using a column to which a fusion protein containing a polypeptide was immobilized, and the Fc region was removed and purified from the product obtained by enzymatic digestion of immunoglobulin G with papain.
- the form of the solid phase carrier and the immobilization method are not limited thereto, and are suitable for protein purification methods known to those skilled in the art, such as particles such as magnetic particles and filter membranes. Applicable to.
- the molecule to be purified can be applied to a fusion protein in which an Fc region is linked to any protein such as a cytokine or an enzyme.
- Methods for measuring polypeptide binding activity include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), isothermal titration calorimeter (ITC), quartz crystal microbalance (QCM), atomic force Examples thereof include a microscope jar (AFM) (Non-Patent Document 24), a pull-down method (Non-Patent Document 25), an electrophoresis method (Non-Patent Document 26), and a fluorescence polarization degree measuring method (Non-Patent Document 27).
- ELISA enzyme-linked immunosorbent assay
- SPR surface plasmon resonance
- ITC isothermal titration calorimeter
- QCM quartz crystal microbalance
- polypeptide and fusion protein of the present invention it is possible to detect and separate (purify or remove) an antibody having a non-natural three-dimensional structure, immunoglobulin G or Fc region-containing protein in a sample.
- a method for detecting an antibody having a non-natural three-dimensional structure, immunoglobulin G or Fc region-containing protein in a test sample can comprise the following steps: (1) contacting a test sample with the polypeptide, protein, transformant, recombinant phage or recombinant virus, or immobilized polypeptide or immobilized protein of the present invention, and (2) A step of determining whether binding has occurred between the test sample and the polypeptide, protein, transformant, recombinant phage or recombinant virus, or immobilized polypeptide or immobilized protein.
- the methods used to determine whether or not the above binding has occurred include ELISA, SPR, ITC, QCM, AFM, pull-down method, electrophoresis method, fluorescence polarization measurement method, fluorescence resonance energy transfer method (FRET), column Examples thereof include chromatography and immunochromatography. In the examples described later, an example of the surface plasmon resonance method is shown, but other technically applicable methods including the above technology are not excluded.
- a method for purifying an antibody having an unnatural conformation, an immunoglobulin G or an Fc region-containing protein may comprise the following steps: (1) A sample containing an antibody having an unnatural type three-dimensional structure, an immunoglobulin G or Fc region-containing protein, a polypeptide, protein, transformant, recombinant phage or recombinant virus of the present invention, or an immobilized polypeptide or An antibody having a non-natural three-dimensional structure, immunoglobulin G or Fc region-containing protein is contacted with an immobilized protein, and the polypeptide, protein, transformant, recombinant phage or recombinant virus, or immobilized polypeptide or Binding to the immobilized protein; and (2) A polypeptide, protein, transformant, recombinant phage or recombinant virus, or an antibody having an unnatural three-dimensional structure bound to an immobilized polypeptide or immobilized protein, an immunoglobulin G or Fc region-containing protein Recover
- Examples of the method used in the step of recovering from the sample include an affinity chromatography method, an affinity bead method, an affinity filter method, and an immunoprecipitation method.
- affinity chromatography methods are shown, but other technically applicable methods including the above-described technology are not excluded.
- a method for removing an antibody having an unnatural conformation, an immunoglobulin G or an Fc region-containing protein may comprise the following steps: (1) A sample containing an antibody having an unnatural type three-dimensional structure, an immunoglobulin G or Fc region-containing protein, a polypeptide, protein, transformant, recombinant phage or recombinant virus of the present invention, or an immobilized polypeptide or An antibody having a non-natural three-dimensional structure, immunoglobulin G or Fc region-containing protein is contacted with an immobilized protein, and the polypeptide, protein, transformant, recombinant phage or recombinant virus, or immobilized polypeptide or Binding to the immobilized protein; and (2) A polypeptide, protein, transformant, recombinant phage or recombinant virus, or an antibody having an unnatural three-dimensional structure bound to an immobilized polypeptide or immobilized protein, an immunoglobulin G or Fc region-containing protein Remov
- Examples of the method used in the step of removing from the sample include an affinity chromatography method, an affinity bead method, an affinity filter method, and an immunoprecipitation method.
- affinity chromatography methods are shown, but other technically applicable methods including the above-described technology are not excluded.
- amino acid sequences of a number of polypeptides exhibiting antibody binding activity were specified was described, and then amino acids of SEQ ID NOs: 2 to 6 containing the amino acid sequence of SEQ ID NO: 1 as a common sequence
- amino acid sequences of SEQ ID NOs: 11 to 14 including the sequence and the amino acid sequence of SEQ ID NO: 10 as a common sequence, and several amino acids within these amino acid sequences as long as the binding activity to the Fc region of immunoglobulin G (IgG) is not lost
- Synthetic polypeptide consisting of the amino acid sequence of SEQ ID NO: 7-9, 15-21, SEQ ID NO: 22 which is part of them, or a fusion protein comprising these amino acid sequences, wherein amino acid substitutions are added, deleted, substituted or inserted
- an example in which the binding activity of a recombinant phage transformed with a nucleic acid encoding these amino acid sequences was measured is shown.
- a polypeptide comprising the amino acid sequence of Tyr-Asp-Pro-Xaa-Thr-Gly-Thr-Trp- (Xaa) 8 -Gly (SEQ ID NO: 168) (where Xaa represents an arbitrary amino acid residue)
- Xaa represents an arbitrary amino acid residue
- a phage library displayed at the C-terminus of the outer protein g10 of T7 phage via a linker consisting of the amino acid sequence of Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 169), and T7Select10-3 Cloning Kit (Novagen) Constructed using. All procedures necessary for construction were in accordance with the attached T7Select (registered trademark) System Manual (Novagen).
- phages that bound to the Fc region of human IgG as the target substance were selected.
- 20 ⁇ g of biotinylated human IgG Fc region Jackson Immunoresearch
- Streptavidin MagneSphere Trademark
- Paramagnetic Particles Promega 0.65 ml used as avidin fixed magnetic beads, and Fc region via avidin-biotin bond.
- the blocking agent SuperBlock (registered trademark) T20 (TBS) Blocking Buffer (Thermo SCIENTIFIC) was added thereto for 1 hour to block the magnetic beads with the Fc region fixed.
- SDS sodium dodecyl sulfate
- step of bringing the library into contact with the Fc region of human IgG as a target substance and the step of selecting and recovering phages bound to the Fc region of human IgG” are repeated five times to present a polypeptide showing binding activity. The phage was concentrated.
- Binding activity test by ELISA and identification of binding activity polypeptide by sequence analysis Subsequently, an example in which molecules having binding activity are identified from an enriched phage population by ELISA and DNA analysis is shown.
- TBS buffer 50 mM Tris-HCl, 150 mM NaCl, pH 7.4
- MEDISORP 96 well microplate NaCl, pH 7.4
- Physical adsorption was performed on the plate.
- the supernatant was removed, 150 ⁇ l of SuperBlock (registered trademark) T20 (TBS) Blocking Buffer (Thermo SCIENTIFIC) was added for 1 hour to block the plate surface, and the plate was washed 3 times with TBS-T buffer.
- the top 16 types of phages with high binding activity were analyzed using ABI PRISM (trademark registration) 3100 (Applied BioSystems) as a polypeptide having binding activity as a result of analyzing the DNA sequence of the region encoding the polypeptide by the dideoxy method.
- ABI PRISM trademark registration
- 3100 Applied BioSystems
- the amino acid sequences shown in SEQ ID NOs: 2 to 9 were identified.
- Xaa is A polypeptide comprising an amino acid sequence (which represents an arbitrary amino acid residue) via a linker comprising an amino acid sequence of Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 169)
- the phage library presented in 1 was constructed using the T7Select10-3 Cloning Kit (Novagen). All procedures necessary for construction were in accordance with the attached T7Select (registered trademark) System Manual (Novagen).
- Example 2 Using this phage library, following the same procedure as in 1) of Example 1, the process of selecting and recovering phages that contact and bind to the Fc region was repeated 6 times to obtain a polypeptide that exhibits binding activity in the Fc region. The displayed phage was concentrated. Subsequently, according to the same procedure as in 2) of Example 1, molecules having binding activity were confirmed from the enriched phage population by ELISA, and DNA sequence analysis was performed by the dideoxy method. As a result of DNA sequence analysis, a polypeptide containing the amino acid sequence represented by SEQ ID NOs: 11 to 19 in which convergence of the amino acid sequence was confirmed was identified as a binding activity polypeptide.
- Polypeptides synthesized organically were purchased from bioSYNTHESIS. Biacore T100 (GE Healthcare) was used as a surface plasmon resonance measuring apparatus. A human Fc region manufactured by Jackson Immunoresearch was immobilized on a sensor chip CM5 (GE Healthcare) by an amine coupling method using an Amine Coupling Kit (GE Healthcare). The polypeptide is then 50, 25, 12.5 ⁇ M for H6, 100, 80, 60, 40, 20 nM for 2A1, 40, 30, 20, 10, 5 ⁇ M for 2A1Gly, 200, 100, 50 for RSS.
- HBS-T buffer (10 mM HEPES, 150 mM NaCl, 0.05% Tween20 (registered trademark), pH 7.4)
- the binding activity was measured at a reaction temperature of 25 ° C.
- the measured data were processed by Biacore T00 Evaluation Software (GE Healthcare) , H6, 2A1, 2A1Gly, RSS avidity bond dissociation trouble K respectively 7.9 ⁇ 10 -5 in the D (M), 2.2 ⁇ 10 -8 ( M), 2.3 ⁇ 10 ⁇ 5 (M), and 1.1 ⁇ 10 ⁇ 4 (M) (Table 1A).
- DNA encoding the polypeptide of amino acid sequence 2, 11-13 was amplified by polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- KOD DNA polymerase TOYOBO
- the amplified DNA is digested with EcoRI and HindIII, and introduced into the region digested at the EcoRI / HindIII site of pET-48b (Invitrogen), thereby encoding the fusion protein linking the polypeptide to the C-terminus of thioredoxin (
- these identified polypeptides and thioredoxin fusion proteins are referred to as H6_trx, 2A1_trx, 2A4_trx, 2F12_trx (SEQ ID NOs: 82 to 85)).
- the cells were sonicated with Astrason Model S3000 (Wakeken) and the intracellular soluble fraction was recovered by centrifugation at 14000 ⁇ g for 20 minutes. This soluble fraction was purified by metal chelate affinity chromatography using Ni Sepharose (registered trademark) 6 Fast Flow (GE Healthcare) to prepare the desired thioredoxin fusion protein.
- the binding activity of the prepared thioredoxin fusion protein was measured by the surface plasmon resonance method.
- Biacore T100 GE Healthcare
- the Fc region manufactured by Jackson Immunoresearch was immobilized on the sensor chip CM5 (GE Healthcare) by the amine coupling method.
- the prepared thioredoxin fusion proteins H6_trx, 2A1_trx, 2A4_trx, 2F12_trx
- H6_trx, 2A1_trx, 2A4_trx, 2F12_trx were adjusted to 600, 500, 400, 300, 200, 100 nM with HBS-T buffer, respectively, and the binding activity was measured at 25 ° C.
- DNAs encoding the amino acid sequences of SEQ ID NOs: 2-9 and 11-19 were amplified by polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- KOD DNA polymerase TOYOBO
- the amplified DNA was digested with restriction enzymes EcoRI and HindIII and then ligated to the 3 ′ end of the g10 gene on T7 phage genomic DNA.
- T7 phage genomic DNA the sample attached to the T7Select10-3 Cloning Kit (Novagen) was used, and the reaction conditions and procedures were in accordance with the attached T7Select (registered trademark) System Manual.
- T7 phage was packaged in vitro by T7Select Packaging Kit (Novagen). The reaction conditions were in accordance with T7Select (registered trademark) System Manual (Novagen). Subsequently, phage plaques were formed according to T7Select (registered trademark) System Manual (Novagen), and a recombinant phage displaying the polypeptide was isolated from each plaque.
- MICROTEST registered trademark
- MICROTEST registered trademark
- 96 BECTON DICKINSON
- coli BL5403 strain cultured in LB medium to OD 600 1.0 was added, and each of the recombinant phages isolated from plaques was infected and incubated at 37 ° C. The phages were amplified by standing for 12 hours. 10 ⁇ l of the culture solution containing these phages was diluted in 90 ⁇ l of TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) to obtain a measurement sample.
- TBS buffer 50 mM Tris-HCl, 150 mM NaCl, pH 7.4
- the measurement sample was placed in a MEDISORP 96 well microplate (Nunc) for 1 hour to physically adsorb the phage onto the plate. The supernatant was removed, 150 ⁇ l of SuperBlock (registered trademark) T20 (TBS) Blocking Buffer (Thermo SCIENTIFIC) was added for 1 hour to block the plate surface, and then TBS-T buffer (50 mM Tris-HCl, 150 mM NaCl, Washed 3 times with 0.1% Tween20 (registered trademark), pH 7.4).
- TBS-T buffer 50 mM Tris-HCl, 150 mM NaCl, Washed 3 times with 0.1% Tween20 (registered trademark), pH 7.4
- TBS-T buffer containing horseradish peroxidase (HRP) -labeled Fc region (Jackson Immunoresearch) (0.2 ⁇ g / ml) was added and allowed to stand for 1 hour. After washing 3 times with TBS-T buffer, 100 ⁇ l of ABTS One Component HRP Microwell Substrate (BioFX) was added to detect binding activity as a color reaction. For the absorbance measurement, an absorbance microplate reader Sunrise R (TECAN) was used, and the absorbance at 415 nm (OD 415 ) was measured. As a control experiment, non-phage TBS-T buffer was used as a negative control.
- HRP horseradish peroxidase
- Table 2A shows the ELISA results for the recombinant phage displaying the polypeptide containing the amino acid sequence shown by SEQ ID NO: 2-9 and the recombinant phage showing the polypeptide containing the amino acid sequence shown by SEQ ID NO: 11-19.
- Table 2B shows. All recombinant phages showed significant binding activity with respect to the control.
- a polypeptide consisting of the amino acid sequence of SEQ ID NO: 11 specifically binds to immunoglobulin G and Fc regions having a non-natural structure.
- An example confirmed to show activity is described.
- non-natural type structure such as Alternative folded state (AFS) by acid treatment shown in “Best Mode for Carrying Out the Invention” above, non-natural type obtained by acid treatment and reducing agent treatment The binding activity to the immunoglobulin G or Fc region of the structure was measured and compared with the binding activity to the native structure.
- AFS Alternative folded state
- the surface plasmon resonance method was used to evaluate the binding activity to the non-natural structure.
- 2A1 was immobilized on sensor chip CM5 by the amine coupling method, and the binding activity to human IgG or Fc region treated under the following multiple conditions was measured. The following were used as measurement samples.
- Fc region (3) (FIG. 1A) was reduced with 50 mM 2-mercaptoethylamine (Thermo Scientific Pierce) at 37 ° C. for 90 minutes, and the reducing conditions were maintained in the presence of 10 mM ethylenediaminetetraacetic acid.
- 2A1 binds to the human Fc region (Fig. 1A) purchased from Jackson Immunoresearch in (1), but (2) human IgG of natural structure (Fig. 1B), and results therefrom.
- the Fc region (3) (FIG.
- polypeptide 2A1 represented by SEQ ID NO: 11 was evaluated in this section.
- Polypeptide 2A1 synthesized organically was diluted to 27 ⁇ M with HBS-T buffer (10 mM HEPES, 150 mM NaCl, 0.05% Tween20 (registered trademark), pH 7.4) and heated at 98 ° C. for 15 minutes.
- the heat-treated and non-heat-treated samples were diluted to 100, 50, 25, and 12.5 nM with HBS-T buffer, respectively, and the binding activity was evaluated by surface plasmon resonance.
- Biacore T100 (GE Healthcare) was used as a surface plasmon resonance measurement device.
- the human Fc region having a non-natural structure was prepared by dialyzing the natural human Fc region into an acid buffer (10 mM Gly-HCl, 150 mM NaCl, pH 2.0).
- This non-natural human Fc region was immobilized on the sensor chip CM5 (GE Healthcare) by the amine coupling method using Amine Coupling Kit (GE Healthcare), and the binding activity was measured at a reaction temperature of 25 ° C. Measurement data was processed with Biacore T00 Evaluation Software (GE Healthcare).
- the binding activity of the heat-treated and non-heat-treated samples was calculated as 2.0 ⁇ 10-8 (M) and 2.2 ⁇ 10-8 (M) as the bond dissociation constant KD, respectively.
- the total amount of binding response was the same for both. The above results indicate that the binding activity of polypeptide 2A1 is not irreversibly impaired even by heat treatment, and exhibits high heat inactivation resistance.
- amino acid sequences of a number of polypeptides exhibiting antibody binding activity were specified was described, and then amino acids of SEQ ID NOs: 24-54 containing the amino acid sequence of SEQ ID NO: 23 as a common sequence
- amino acid sequence of SEQ ID NO: 57 to 72 containing the sequence and the amino acid sequence of SEQ ID NO: 56 as a common sequence, and several amino acid residues in these amino acid sequences as long as the binding activity to the Fc region of IgG is not impaired Added, deleted, substituted or inserted polypeptide consisting of the amino acid sequence of SEQ ID NO: 55, 73-81, a fusion protein containing these amino acid sequences, or a group transformed with a nucleic acid encoding these amino acid sequences
- the example which measured the binding activity of the replacement phage is shown.
- a step of bringing the library into contact with the Fc region of human IgG, which is a target substance, and a step of selecting and recovering a phage bound to the Fc region of human IgG are shown.
- the Fc region was prepared by affinity chromatography using MabSelect SuRe (GE Healthcare) after human IgG antibody IgG was digested with papain according to the instructions attached to Pierce (registered trademark) Fab Preparation Kit (Thermo SCIENTIFIC Pierce). Purified by gel filtration chromatography using HiTrap DEAE anion exchange chromatography (GE Healthcare) and Superdex200 (GE Healthcare).
- the prepared Fc region was chemically bonded with biotin via an amino group using D-Biotinoyl- ⁇ -Aminocaproic Acid N-Hydroxysuccinimide Ester (Roche) according to the attached instruction. Subsequently, following the same procedure as in Example 1 1) and 2), the step of contacting the library with the Fc region and selecting and recovering the phage bound thereto, and the phage displaying the polypeptide having binding activity by ELISA The step of confirmation, DNA sequence analysis by dideoxy method was performed. As a result, the amino acid sequence represented by SEQ ID NOs: 24-55 was identified as a polypeptide showing binding activity.
- the “step of selecting and collecting phages that contact and bind to the Fc region” was repeated 10 times according to the same procedure as in 1) of Example 2.
- the binding activity test and DNA sequence analysis by ELISA were carried out in the same manner as in 2) IV of Example 1, and the amino acid sequence consisting of SEQ ID NOs: 57 to 81 was specified as the binding activity polypeptide.
- This section shows an example in which the binding activity of polypeptides consisting of amino acid sequences of SEQ ID NOs: 24-27 (referred to as pep14, pep11, pep21, and pep24, respectively) was measured by surface plasmon resonance.
- the organically synthesized polypeptide was purchased from bioSYNTHESIS. This was diluted with HBS-T buffer and adjusted to 500, 400, 300, 200, 100 nM. BiacoreT100 (GE Healthcare) was used for the surface plasmon resonance test.
- the Fc region to be immobilized on the sensor chip was obtained by digesting human monoclonal IgG with papain according to the instructions attached to the Pierce (registered trademark) Fab Preparation Kit (Thermo SCIENTIFIC), followed by affinity chromatography using MabSelect SuRe (GE Healthcare), HiTrap It was prepared by purification by gel filtration chromatography using DEAE anion exchange chromatography (GE Healthcare) and Superdex200 (GE Healthcare). The prepared Fc region was immobilized on a sensor chip CM5 (GE Healthcare) by an amine coupling method. The binding activity was measured using the prepared synthetic peptide, and the binding dissociation constant was measured.
- p17 the binding activity of the polypeptide consisting of the amino acid sequence of SEQ ID NO: 57 (referred to as p17) is measured by surface plasmon resonance.
- the polypeptide was prepared by cleaving the thioredoxin fusion protein p17_trx consisting of the amino acid sequence of SEQ ID NO: 86 with protease and then removing the thioredoxin moiety.
- the thioredoxin fusion protein produced by the expression vector pET-48b (Novagen) ⁇ has an HRV 3C protease cleavage site in its amino acid sequence, so that the desired polypeptide linked to the C-terminus can be obtained using this protease. .
- DNA (SEQ ID NO: 124) encoding thioredoxin fusion protein (SEQ ID NO: 86) containing p17 was synthesized by PCR, and this DNA was introduced into the expression vector pET-48b (Novagen). Using this expression vector, a thioredoxin fusion protein was prepared according to the same procedure as in Example 1, 5). A thioredoxin fusion protein 40 mg was digested at 4 ° C using HRV 3C Protease (Novagen) 100 Unit. Reaction conditions followed the attached manual.
- the reaction product is diluted in 6M guanidine hydrochloride solution, gel filtration chromatography using Superdex Peptide 10/300 GL (GE Healthcare), then reverse phase chromatography using ⁇ RPC C2 / C18 ST 4.6 / 100 (GE Healthcare).
- the polypeptide p17 consisting of the amino acid sequence of SEQ ID NO: 57 was prepared.
- This value shows extremely high binding activity as a linear polypeptide.
- protein protein A or protein G respectively 1.0 ⁇ 10 -8 (M) (Non-patent in the binding activity K D of each domain alone Reference 28) It is about 4.9 ⁇ 10 ⁇ 7 (M) (Non-patent Reference 29).
- DNAs encoding the polypeptides of SEQ ID NOs: 24, 26-33, 57-81 were amplified by PCR. These are digested with EcoRI and HindIII, and introduced into the regions digested at the EcoRI / HindIII sites of pET-48b (Invitrogen), respectively, so that a fusion protein (SEQ ID NO: 87 to 95, SEQ ID NOS: 87 to 95, DNA coding for 86, 98, 99, 101, 102, 106-113, 116-118, 96, 97, 100, 103-105, 114, 115, 119 (SEQ ID NOs: 125-133, 124, 136, 137) , 139, 140, 144-151, 154-156, 134, 135, 138, 141-143, 152, 153, 157) were constructed. Using this expression vector, a thioredoxin fusion protein was prepared according to the same procedure as in Example 1, 5).
- the binding activity of the prepared thioredoxin fusion protein was measured by the surface plasmon resonance method.
- Biacore T100 GE Healthcare
- the Fc region was immobilized on the sensor chip CM5 (GE Healthcare) by the amine coupling method according to the same procedure as in Example 2, 3).
- the prepared thioredoxin fusion protein was adjusted to 600, 500, 400, 300, 200, and 100 nM with HBS-T buffer, and the binding activity was measured at 25 ° C. Data were processed with Biacore T00 Evaluation Software (GE Healthcare). The calculated K D shown in Table 4.
- DNAs encoding the amino acid sequences of SEQ ID NOs: 26, 27, 30 to 55, 57, 63 to 72, and 79 to 81 were amplified by polymerase chain reaction.
- KOD DNA polymerase TOYOBO
- the amplified DNA was digested with restriction enzymes EcoRI and HindIII and then ligated to the 3 ′ end of the g10 gene on T7 phage genomic DNA.
- T7 phage genomic DNA the sample attached to the T7Select10-3 Cloning Kit (Novagen) was used, and the reaction conditions and procedures were in accordance with the attached T7Select (registered trademark) System Manual.
- T7 phage was packaged in vitro by T7Select Packaging Kit (Novagen). The reaction conditions were in accordance with T7Select (registered trademark) System Manual (Novagen). Subsequently, phage plaques were formed according to T7Select (registered trademark) System Manual (Novagen), and a recombinant phage displaying the polypeptide was isolated from each plaque.
- MICROTEST registered trademark
- MICROTEST registered trademark
- 96 BECTON DICKINSON
- coli BL5403 strain cultured in LB medium to OD 600 1.0 was added, and each of the recombinant phages isolated from plaques was infected and incubated at 37 ° C. The phages were amplified by standing for 12 hours. 10 ⁇ l of the culture solution containing these phages was diluted in 90 ⁇ l of TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) to obtain a measurement sample.
- TBS buffer 50 mM Tris-HCl, 150 mM NaCl, pH 7.4
- the measurement sample was placed in a MEDISORP 96 well microplate (Nunc) for 1 hour to physically adsorb the phage onto the plate. The supernatant was removed, 150 ⁇ l of SuperBlock (registered trademark) T20 (TBS) Blocking Buffer (Thermo SCIENTIFIC) was added for 1 hour to block the plate surface, and then TBS-T buffer (50 mM Tris-HCl, 150 mM NaCl, Washed three times with 0.1% Tween20 (registered trademark), pH 7.4).
- TBS-T buffer 50 mM Tris-HCl, 150 mM NaCl, Washed three times with 0.1% Tween20 (registered trademark), pH 7.4
- TBS-T buffer containing horseradish peroxidase (HRP) -labeled Fc region (Jackson Immunoresearch) (0.2 ⁇ g / ml) was added and allowed to stand for 1 hour. After washing 3 times with TBS-T buffer, 100 ⁇ l of ABTS One Component HRP Microwell Substrate (BioFX) was added to detect binding activity as a color reaction. For the absorbance measurement, an absorbance microplate reader Sunrise R (TECAN) was used, and the absorbance at 415 nm (OD 415 ) was measured. As a control experiment, non-phage TBS-T buffer was used as a negative control.
- HRP horseradish peroxidase
- Recombinant phage presenting a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 26, 27, 30 to 55
- the results of ELISA for the phage are shown in Table 5A and Table 5B, respectively. All recombinant phages showed significant binding activity with respect to the control.
- This example shows an example in which non-natural IgG mixed in a trace amount in a natural IgG sample is quantitatively detected by using the synthetic peptide 2A1 represented by SEQ ID NO: 11.
- chromatography techniques such as size exclusion chromatography are widely used as one of quick and simple heterogeneity evaluations (Non-patent Document 30).
- the usefulness of the detection technique using the polypeptide of the present invention was verified by comparison with size exclusion chromatography, which is a general-purpose technique.
- Non-natural IgG was obtained by dialysis of human monoclonal antibody against 10 mM Glycine-HCl, 150 mM NaCl, pH 2.0, which is known to produce AFS for 18 hours.
- the prepared non-natural IgG is neutralized with Tris-HCl (pH 8.0) and then diluted to a natural IgG (6.7 ⁇ M) diluted in HBS-T buffer (10, 5, 1, 0.1, 0.01, 0.001). %) was mixed with non-natural IgG and used as a measurement sample.
- the measurement sample was analyzed using surface plasmon resonance and size exclusion chromatography, and the detection sensitivity of non-natural IgG was compared.
- the measuring apparatus and sensor chip described in 7) of Example 1 were used.
- the measurement data of the prepared sample was analyzed using Bicore T100 Evaluation Software (GE Healthcare), and the amount of unnatural IgG mixed was quantified as a binding response (FIG. 2).
- AKTA purifier GE Healthcare
- Superdex 200 5/150 GL GE Healthcare
- the measurement data is processed using UNICORN version 4.12 (GE Healthcare), and the amount of unnatural IgG is quantified using the peak areas detected as the monomeric and multimeric fractions of IgG ( Figure 3). did.
- FIG. 4 is a graph comparing the logarithm plots of the detected amount of AFS type IgG obtained by the surface plasmon resonance method and size exclusion chromatography with respect to the concentration of AFS type IgG.
- the size exclusion chromatography can show a significant detection sensitivity up to a contamination rate of 0.1%.
- non-natural IgG can be detected due to the high binding activity of the polypeptide. Since it was possible to detect with high sensitivity, it was revealed that sufficient detection sensitivity was exhibited even at a contamination rate of 0.01%. That is, the results of this example show that non-natural IgG mixed in a trace amount of natural IgG such as antibody drugs can be detected with higher accuracy than existing methods by using non-natural IgG binding polypeptide. It is shown.
- an affinity column was prepared by immobilizing a thioredoxin fusion protein p17_trx (SEQ ID NO: 86) ⁇ ⁇ fused with an IgG binding polypeptide, and this was used to remove and purify the Fc region, and human An example applied to the purification of IgG is shown.
- the polypeptide of the present invention binds to the Fc region of IgG with a binding dissociation constant in the nM order, and is comparable to an existing IgG-binding protein, IgG-binding polypeptide, or these. Has superior binding activity. Based on this high binding activity, it was applied as an affinity column that can be suitably used for selective removal of Fc region or IgG purification.
- mutants in which a single amino acid residue mutation is introduced into the amino acid sequence of polypeptide 2A1 represented by SEQ ID NO: 11 SEQ ID NOs: 158 to 164.
- SEQ ID NOs: 158 to 164 An example in which the binding activity of each amino acid residue was measured by surface plasmon resonance and the influence of each amino acid residue on binding was evaluated.
- 2A1_Q5R (SEQ ID NO: 158), 2A1_W6A (SEQ ID NO: 159), 2A1_S7A (SEQ ID NO: 160), 2A1_R17A (SEQ ID NO: 161), 2A1_S18A (SEQ ID NO: 162), 2A1_S19A (SEQ ID NO: 163) and 2A1_I20A (SEQ ID NO: 164) were purchased from bioSYNTHESIS. Biacore T100 (GE Healthcare) was used as a surface plasmon resonance measuring apparatus.
- the human Fc region having a non-natural structure was prepared by dialyzing the natural human Fc region into an acid buffer (10 mM Gly-HCl, 150 mM NaCl, pH 2.0). This non-natural human Fc region was immobilized by the amine coupling method using Amine Coupling Kit (GE Healthcare) on sensor chip CM5 (GE Healthcare).
- the polypeptide is then 62.5, 31.3, 15.6 nM for Q5R, 500, 250, 125 nM, W7A for 1000, 500, 250 nM, R17A, 500, 250, 125 nM, 125 for S18A, 125, 62.5, 31.3 nM, S19A 1000, 500, 250 nM, I20A 500, 250, 125 nM up to HBS-T buffer (10 mM HEPES, 150 mM NaCl, 0.05% Tween20 (trademark registration), pH 7.4 ), And the binding activity was measured at a reaction temperature of 25 ° C.
- the measurement data Biacore T00 Evaluation was treated with Software (GE Healthcare), it was calculated Q5R, W6A, S7A, R17A, S18A, S19A, and the respective binding dissociation constant, K D, of I20A (Table 6). As a result, it was found that the binding activity increased 2.5-fold by mutating the glutamine residue at position 5 to an arginine residue.
- the tryptophan residue at position 6 was approximately 1/8
- the serine residue at position 7 was approximately 1/5
- position 17, respectively The arginine residue was reduced by about 1/16
- the serine residue at position 19 was reduced by about 1/10
- the isoleucine residue at position 20 was reduced by about 1/50. This result indicates that these residues are greatly involved in the expression of binding activity.
- the Fc region of the target human IgG is recovered from a solution containing a contaminating protein.
- polypeptide 2A1 0.5 mg was dissolved in 1.5 ml of sodium carbonate buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3), and this was added to 0.1 ml of NHS-activated Sepharose (registered trademark) (GE Healthcare) in an amine cup. Immobilized by the ring method. The immobilization procedure followed the attached package insert. The immobilization reaction rate was 42%.
- 1 ml of TBS-T buffer solution 50 mM Tris-HCl, 150 mM NaCl, 0.05% (w / v) Tween20 (registered trademark) was used for E. coli BLT5403 strain cultured in 1 ml of LB medium.
- the human Fc region having a non-natural structure was prepared by dialysis of the natural human Fc region against glycine hydrochloride buffer (10 mM Glycine-HCl, 150 mM NaCl, pH 2.0). A solution obtained by adding 5 ⁇ g of this non-natural Fc region to 62 ⁇ l of the above E. coli disruption solution and diluting it to 1 ml with TBS-T buffer was used as a sample solution for binding specificity evaluation. As a control solution for a comparative test, an E. coli disruption solution containing no non-natural Fc region was prepared.
- the prepared sample solution and Sepharose to which 2A1 peptide was immobilized were mixed for 20 minutes. Thereafter, the plate was washed 5 times with 0.5 ml of TBS-T buffer and eluted with 0.2 ml of 50 mM NaOH. The eluate was neutralized with 10 ⁇ l of 3M sodium acetate (pH 5.2). The eluate and sample solution were analyzed by SDS polyacrylamide gel electrophoresis (FIG. 8). Only a band corresponding to the Fc region was significantly present in the eluate as compared with other contaminating proteins. This result indicates that polypeptide 2A1 specifically recognizes the target Fc region among a number of contaminating proteins, and the molecule obtained by the present invention is high in normal protein-protein interactions. It shows that it has target specificity.
- polypeptide p17 followed the same procedure as in Example 2, 4).
- the Fc region of human IgG was prepared according to the same procedure as in Example 2 1).
- the complex of polypeptide p17 and Fc region was dialyzed against a buffer solution (20 mM Tris-HCl, 10% (v / v) dimethyl sulfoxide, pH 7.4), and concentrated to a concentration of 10 mg / ml by ultrafiltration. Crystals were obtained by a sitting-drop vapor diffusion method using 40% polyethylene glycol 4000, 0.1 M sodium citrate (pH 5.6), 0.2 M ammonium acetate as a crystallization precipitant / buffer solution.
- Polypeptide p17 was formed of 4 ⁇ strands, 3 ⁇ hairpins, 1 short ⁇ helix, and 1 loop structure (FIG. 9).
- PDB code, 1DN2 the binding site to the Fc region was recognized as an equivalent site (FIG. 11). This indicates that the enhancement of the function of the peptide according to the present invention can be enhanced without impairing the characteristics of the original function.
- the region derived from signoline introduced into the library formed a ⁇ hairpin as in the case of signoline, and was responsible for arranging the region extended as a random amino acid sequence in the vicinity of Fc-III Ala. This indicates that the use of microproteins that form ⁇ hairpins is responsible for effectively bringing the two segments in close proximity.
- the two regions extended as random amino acid sequences formed completely different three-dimensional structures.
- the C-terminal region formed a short ⁇ -helix, and the side chain protruding from the helix surface was in contact with the amino acid residue of Fc-III Ala, supporting a conformation favorable for binding (FIG. 12).
- Non-patent Documents 3 and 4 which corresponds to Fc-III Ala.
- the aromatic ring residue of Trp33 was directly supported by the side chain of Met51 present in the ⁇ helix (Fig. 12).
- the N-terminal formed a loop structure and supported this foundation by contacting the introduced signoline part, which is the foundation of Fc-III Ala (Fig. 12).
- a mutant in which the amino acid residue present in the C-terminal segment of p17 polypeptide (SEQ ID NO: 57) ⁇ is substituted with alanine is prepared, and the binding activity is measured, so that the amino acid residue becomes binding activity.
- An example is shown in which the role of these amino acid residues is analyzed in detail by evaluating the influence of the amino acid residues and comparing the three-dimensional structure information obtained in Example 7.
- DNAs (SEQ ID NOs: 179 to 183) encoding amino acid sequences represented by SEQ ID NOs: 174 to 178 were designed and synthesized by PCR. According to the same procedure as in Example 2, 4), a mutant polypeptide was prepared by expression of thioredoxin fusion protein and protease treatment and named as follows: p17_P46A (SEQ ID NO: 174), p17_D47A (SEQ ID NO: 175), p17_W48A (SEQ ID NO: 176), p17_R50A (SEQ ID NO: 177), p17_M51A (SEQ ID NO: 178).
- the site where the alanine substitution was introduced was considered from a structural viewpoint.
- the main chain of the polypeptide changes direction due to the structural orientation characteristic of the proline residue, and plays a role in fine-tuning the ⁇ -helix that occurs ahead to the appropriate position.
- Figure 13A Asp47 is hydrogen-bonded with nearby Arg50 (FIG. 13B), and finely adjusts the orientation of the ⁇ helix as in Pro46.
- Arg50 present in the ⁇ -helix assisted cross-linking between ⁇ -strands at positions 23 to 35 forming a binding site by contacting the side chain with Ala24 (FIG. 13C).
- Trp48 and Met51 present in the ⁇ helix are in contact with each other at these hydrophobic residues centering on Met51, and directly stabilized the aromatic ring of Trp33 present in the binding site (FIG. 13D).
- Non-Patent Documents 3 and 4 it is shown that the orientation of the aromatic ring side chain of Trp33 greatly affects the binding to the Fc region.
- substitution of alanine in Met51 leads to a binding affinity decrease of 100 times or more. From these two facts, it is considered that the binding involvement of Met51 enhances the binding activity by supporting the aromatic ring of Trp33.
- the present invention is useful for detection, purification, immobilization or removal of proteins including antibodies.
- SEQ ID NO: 1 IgG binding peptide
- SEQ ID NO: 2 IgG binding peptide
- H6 SEQ ID NO: 3 IgG binding peptide
- H3 SEQ ID NO: 4 IgG binding peptide
- D5 SEQ ID NO: 5 IgG binding peptide
- E7 SEQ ID NO: 6 IgG binding peptide
- sC12 SEQ ID NO: 7 IgG binding peptide
- G3 SEQ ID NO: 8 IgG binding peptide
- sA7 SEQ ID NO: 10 IgG binding peptide
- SEQ ID NO: 11 IgG binding peptide
- 2A1 SEQ ID NO: 12 IgG binding peptide
- 2A4 SEQ ID NO: 13 IgG binding peptide
- 2F12 SEQ ID NO: 14 IgG binding peptide
- 2H1 SEQ ID NO: 15 IgG binding peptid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
[1] 下記式1:
Y-D-P-x-T-G-T-W-R-S-x-[IL] (配列番号1) (1)
(式中、xは任意のアミノ酸残基を表す。 [ ]は[ ]内のアミノ酸残基のいずれか一つを表す。)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[2] 配列番号2~6:
YDPRTGTWRSSIAYGGG (配列番号2)
YDPGTGTWRSYLRFGGG (配列番号3)
YDPYTGTWRSSIWVLSG (配列番号4)
YDPGTGTWRSWLSFNVG (配列番号5)
YDPWTGTWRSFIWGGGG (配列番号6)
のいずれかで表されるアミノ酸配列からなる、[1]に記載のポリペプチド;
[3] 配列番号2~6のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[4] 配列番号7~9:
YDPRTGTWLLYASRLLG (配列番号7)
YDPVTGTWTSSIASWMG (配列番号8)
YDPRTGTWRRSSLSYSG (配列番号9)
のいずれかで表されるアミノ酸配列からなる、[3]に記載のポリペプチド;
[5] 下記式2:
R-[QRS]-x-x-[GS]-Y-D-P-R-T-G-T-W-R-S-S-I-A-Y-G-G (配列番号10) (2)
(式中、xは任意のアミノ酸残基を表す。[ ]は[ ]内のアミノ酸残基のいずれか一つを表す。)で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[6] 配列番号11~14:
GVVRQWSGYDPRTGTWRSSIAYGGG (配列番号11)
AGSRRAHGYDPRTGTWRSSIAYGGG (配列番号12)
ASVRSWSSYDPRTGTWRSSIAYGGG (配列番号13)
SWRRRGSSYDPRTGTWRSSIAYGGG (配列番号14)
のいずれかで表されるアミノ酸配列からなる、[5]に記載のポリペプチド;
[7] 配列番号11~14のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[8] 配列番号15~19、及び158~164:
TGRGRSARYDPRTGTWRSSIAYGGG (配列番号15)
HWVNGRSGYDPRTGTWRSSIAYGGG (配列番号16)
ERWITWSGYDPRTGTWRSSIAYGGG (配列番号17)
GSVVRWRGYDPRTGTWRSSIAYGGG (配列番号18)
GAVYRRSFYDPRTGTWRSSIAYRGG (配列番号19)
GVVRRWSGYDPRTGTWRSSIAYGGG (配列番号158)
GVVRQAQSGYDPRTGTWRSSIAYGGG (配列番号159)
GVVRQWAGYDPRTGTWRSSIAYGGG (配列番号160)
GVVRQWSGYDPRTGTWASSIAYGGG (配列番号161)
GVVRQWSGYDPRTGTWRASIAYGGG (配列番号162)
GVVRQWSGYDPRTGTWRSAIAYGGG (配列番号163)
GVVRQWSGYDPRTGTWRSSAAYGGG (配列番号164)
のいずれかで表されるアミノ酸配列からなる、[7]に記載のポリペプチド;
[9] 下記式3:
G-V-V-R-Q-W-S-G-x-x-x-x-x-x-x-x-R-S-S-I-A-Y-G-G (配列番号20) (3)
(式中、xは任意のアミノ酸残基を表す)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[10] 配列番号21:
GVVRQWSGGGGSGGGGRSSIAYGGG (配列番号21)
で表されるアミノ酸配列からなる、[9]に記載のポリペプチド;
[11] 配列番号22:
RSSIAYGGG (配列番号22)
で表されるアミノ酸配列からなる、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[12] 下記式4:
D-A-A-W-H-L-G-E-L-V-W-A-T-Y-Y-D-P-E-T-G-T-W-x-P-D-W-x-x-M
(配列番号23) (4)
(式中、xは任意のアミノ酸残基を表す)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[13] 配列番号24~54:
DAAWHLGELVWATYYDPETGTWQPDWLYMTTR (配列番号24)
DAAWHLGELVWATYYDPETGTWAPDWRLMQGQ (配列番号25)
DAAWHLGELVWATYYDPETGTWLPDWQTMAQK (配列番号26)
DAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号27)
DAAWHLGELVWATYYDPETGTWQPDWRAMSGR (配列番号28)
DAAWHLGELVWATYYDPETGTWRPDWKWMSTH (配列番号29)
DAAWHLGELVWATYYDPETGTWEPDWKLMQRP (配列番号30)
DAAWHLGELVWATYYDPETGTWQPDWDIMAGH (配列番号31)
DAAWHLGELVWATYYDPETGTWLPDWDVMVRQ (配列番号32)
DAAWHLGELVWATYYDPETGTWVPDWERMKQH (配列番号33)
DAAWHLGELVWATYYDPETGTWEPDWSKMRPQ (配列番号34)
DAAWHLGELVWATYYDPETGTWRPDWAVMATP (配列番号35)
DAAWHLGELVWATYYDPETGTWKPDWRMMGVP (配列番号36)
DAAWHLGELVWATYYDPETGTWLPDWDYMSSK (配列番号37)
DAAWHLGELVWATYYDPETGTWMPDWDRMLRR (配列番号38)
DAAWHLGELVWATYYDPETGTWTPDWNAMSQR (配列番号39)
DAAWHLGELVWATYYDPETGTWQPDWKRMTSR (配列番号40)
DAAWHLGELVWATYYDPETGTWQPDWGRMNSK (配列番号41)
DAAWHLGELVWATYYDPETGTWAPDWNRMRDFNRSFREV (配列番号42)
DAAWHLGELVWATYYDPETGTWVPDWDAMSSR (配列番号43)
DAAWHLGELVWATYYDPETGTWIPDWTRMQTW (配列番号44)
DAAWHLGELVWATYYDPETGTWKPDWQRMKLH (配列番号45)
DAAWHLGELVWATYYDPETGTWLPDWSQMRPQ (配列番号46)
DAAWHLGELVWATYYDPETGTWLPDWDTMTPR (配列番号47)
DAAWHLGELVWATYYDPETGTWQPDWSVMKSL (配列番号48)
DAAWHLGELVWATYYDPETGTWVPDWDTMHAAINRSFREV (配列番号49)
DAAWHLGELVWATYYDPETGTWIPDWRAMSQF (配列番号50)
DAAWHLGELVWATYYDPETGTWLPDWNLMGQH (配列番号51)
DAAWHLGELVWATYYDPETGTWRPDWARMEPM (配列番号52)
DAAWHLGELVWATYYDPETGTWKPDWQVMSPVSNRSFREV (配列番号53)
DAAWHLGELVWATYYDPETGTWQPDWEIMRPF (配列番号54)
のいずれかで表されるアミノ酸配列からなる、[12]に記載のポリペプチド;
[14] 配列番号24~54のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[15] 配列番号55:
EAWHLGELVWATYYDPETGTWRPDWSRMSGR (配列番号55)
で表されるアミノ酸配列からなる、[14]に記載のポリペプチド;
[16] 下記式5:
[RSG]-[AGV]-x-Y-D-P-E-T-G-T-W-Y-D-A-A-W-H-L-G-E-L-V-W-A-T-Y-Y-D-P-E-T-G-T-W-E-P-D-W-Q-R-M-L-G-Q (配列番号56) (5)
(式中、xは任意のアミノ酸残基を表す。[ ]は[ ]内のアミノ酸残基のいずれか一つを表す。)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[17] 配列番号57~72:
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号57)
VISLGSDRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号58)
IMSVDGSSARYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号59)
VDLRAHGGAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号60)
WSRFSSRSVAYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号61)
GNPSDSASAWYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号62)
SNFVRSPSAWYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号63)
IPYGFPGRGEYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号64)
GPYNIPDSAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号65)
WPLNAPSSAFYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号66)
VPPRFSSSAQYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号67)
FLVGLHAGAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号68)
VVRVDHSSAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号69)
WMEFYPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号70)
DGVGPGSRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号71)
FVSSLPNSAMYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号72)
のいずれかで表されるアミノ酸配列からなる、[16]に記載のポリペプチド;
[18] 配列番号57~72のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[19] 配列番号73~81、及び174~178:
GRAFSGSRRWYDPETGTWYDAAWHLGELVWATYYDPETGTWAPDWRLMQGQ (配列番号73)
VMATEVVRGVYDPETGTWYDATWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号74)
MMVRPPRLGVYDPEPGTWYDATWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号75)
ERHLVSDYLHYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号76)
FSDLDSFGVSYDPETGTWYDAAWHRGELVWATYYDPETGTWEPDWQRMLGQ (配列番号77)
LFDNKLKHASYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号78)
GSCKFSSSCHYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号79)
LIPPGGISPWYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号80)
LNDFLTPTAWYDPETGTWYDAAWHLGELVWATYYDPETGTWLPDWQTMAQK (配列番号81)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEADWQRMLGQ (配列番号174)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPAWQRMLGQ (配列番号175)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDAQRMLGQ (配列番号176)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQAMLGQ (配列番号177)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRALGQ (配列番号178)
のいずれかで表されるアミノ酸配列からなる、[18]に記載のポリペプチド;
[20] [1]、[3]、[5]、[7]、[9]、[12]、[14]、[16]、及び[18]のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端に第2のポリペプチドを伸張した連結型ポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド;
[21] 配列番号2~9、11~19、21、22、24~55、57~81、158~164、及び174~178のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端に第2のポリペプチドを伸張した連結型ポリペプチドであることを特徴とする、[20]に記載のポリペプチド;
[22] [1]、[3]、[5]、[7]、[9]、[12]、[14]、[16]、及び[18]のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端にタンパク質を結合した融合タンパク質であって、免疫グロブリンGのFc領域に対する結合活性を示すタンパク質;
[23] 配列番号2~9、11~19、21、22、24~55、57~81、158~164、及び174~178のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端にタンパク質を結合した融合タンパク質であることを特徴とする、[22]に記載のタンパク質;
[24] 配列番号82~119のいずれかで表されるアミノ酸配列からなる、[22]に記載のタンパク質;
[25] [1]~[24]のいずれかに記載のポリペプチドあるいはタンパク質をコードする核酸;
[26] 配列番号120~157、及び179~183のいずれかで表される塩基配列からなる、[25]に記載の核酸;
[27] [25]又は[26]に記載の核酸を含有する組換えベクター;
[28] [27]に記載の組換えベクターが導入された形質転換体;
[29] [25]又は[26]に記載の核酸を含有する組換えファージ又は組換えウイルス;
[30] [1]、[3]、[5]、[7]、[9]、[12]、[14]、[16]、及び[18]のポリペプチド、[20]の連結型ポリペプチド、並びに[22]の融合タンパク質のいずれかに有機化合物あるいは無機化合物あるいは有機化合物と無機化合物の両方が結合した修飾ポリペプチド又は修飾タンパク質であって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド又はタンパク質;
[31] 配列番号2~9、11~19、21、22、24~55、57~81、158~164、及び174~178のポリペプチド、並びに配列番号82~119の融合タンパク質のいずれかに有機化合物あるいは無機化合物あるいは有機化合物と無機化合物の両方が結合した修飾ポリペプチド又は修飾タンパク質であって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド又はタンパク質;
[32] [1]~[21]のいずれかに記載のポリペプチド、[22]~[24]のいずれかに記載のタンパク質、又は[30]~[31]のいずれかに記載のポリペプチド若しくはタンパク質が、水不溶性の固相支持体に固定化されていることを特徴とする、固定化ポリペプチド又は固定化タンパク質;
[33] [1]~[21]のいずれかに記載のポリペプチド、[22]~[24]のいずれかに記載のタンパク質、[25]~[26]のいずれかに記載の核酸、[27]に記載の組換えベクター、[28]に記載の形質転換体、[29]に記載の組換えファージ又は組換えウイルス、[30]~[31]のいずれかに記載のポリペプチド又はタンパク質、及び[32]に記載の固定化ポリペプチド又は固定化タンパク質からなる群より選択される少なくとも1つを含む、抗体、免疫グロブリンGあるいは免疫グロブリンGのFc領域を含有するタンパク質を検出、精製、固定化又は除去するためのキット;
[34] 被検試料中の非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を検出するための方法であって、
(1) 被検試料を、[1]~[21]のいずれかに記載のポリペプチド、[22]~[24]のいずれかに記載のタンパク質、[28]に記載の形質転換体、[29]に記載の組換えファージ若しくは組換えウイルス、[30]~[31]のいずれかに記載のポリペプチド若しくはタンパク質、又は[32]に記載の固定化ポリペプチド若しくは固定化タンパク質と接触させる工程、及び
(2) 被検試料と、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質との間で結合が生じたか否かを判定する工程、
を含む方法;
[35] 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を精製するための方法であって、
(1) 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を含む試料を[1]~[21]のいずれかに記載のポリペプチド、[22]~[24]のいずれかに記載のタンパク質、[28]に記載の形質転換体、[29]に記載の組換えファージ若しくは組換えウイルス、[30]~[31]のいずれかに記載のポリペプチド若しくはタンパク質、又は[32]に記載の固定化ポリペプチド若しくは固定化タンパク質と接触させて、非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合させる工程、及び
(2) ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合した非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を試料から回収する工程、
を含む方法;
[36] 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を除去するための方法であって、
(1) 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を含む試料を[1]~[21]のいずれかに記載のポリペプチド、[22]~[24]のいずれかに記載のタンパク質、[28]に記載の形質転換体、[29]に記載の組換えファージ若しくは組換えウイルス、[30]~[31]のいずれかに記載のポリペプチド若しくはタンパク質、又は[32]に記載の固定化ポリペプチド若しくは固定化タンパク質と接触させて、非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合させる工程、及び
(2) ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合した非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を試料から除去する工程、
を含む方法;
[37] 還元的環境下において実施される、[34]~[36]のいずれかに記載の方法。
(1) 被検試料を、本発明のポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と接触させる工程、及び
(2) 被検試料と、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質との間で結合が生じたか否かを判定する工程。
(1) 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を含む試料を本発明のポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と接触させて、非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合させる工程、及び
(2) ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合した非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を試料から回収する工程。
(1) 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を含む試料を本発明のポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と接触させて、非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合させる工程、及び
(2) ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合した非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を試料から除去する工程。
抗体結合活性を示すポリペプチドのアミノ酸配列は、T7ファージを用いたファージ提示法によって特定した。
続いて、濃縮したファージ集団から、結合活性を有する分子をELISAとDNA解析によって特定した例を示す。
実施例1の2)で特定された分子の高機能化を目的として、アミノ酸配列 (配列番号2) のN末端側に8残基長のランダム配列(Xaa)8を伸長したライブラリを用いた選択を行った。
抗体結合活性を示すポリペプチドのアミノ酸配列は、T7ファージを用いたファージ提示法によって特定した。
実施例2の1)で特定された結合活性ポリペプチドの高機能化を目的として、それぞれ2種類のアミノ酸配列 (配列番号26或いは27) のN末端側を伸長したポリペプチドのファージ提示ライブラリを用いた選択を行った。まず、(Xaa)10 - Tyr - Asp - Pro - Glu - Thr - Gly - Thr - Trp - Tyr - Asp - Ala - Ala - Trp - His - Leu - Gly - Glu - Leu - Val - Trp - Ala - Thr - Tyr - Tyr - Asp - Pro - Glu - Thr - Gly - Thr - Trp - Leu - Pro - Asp - Trp - Gln - Thr - Met - Ala - Gln - Lys(配列番号172) 、或いは、 (Xaa)10 - Tyr - Asp - Pro - Glu - Thr - Gly - Thr - Trp - Tyr - Asp - Ala - Ala - Trp - His - Leu - Gly - Glu - Leu - Val - Trp - Ala - Thr - Tyr - Tyr - Asp - Pro - Glu - Thr - Gly - Thr - Trp - Glu - Pro - Asp - Trp - Gln - Arg - Met - Leu - Gly - Gln(配列番号173) (ここでXaaは任意のアミノ酸残基を示す) のアミノ酸配列からなるポリペプチドを、Gly - Gly - Gly - Gly - Ser(配列番号169)のアミノ酸配列からなるリンカーを介してT7ファージの外殻タンパク質g10のC末端に提示したファージライブラリを、T7Select1-1 Cloning Kit (Novagen) を用いて構築した。構築に必要な手順は全て付属のT7Select(商標登録) System Manual (Novagen) に従った。
の結合活性を表面プラズモン共鳴によって測定し、各アミノ酸残基が結合に与える影響について評価した例を示す。
配列番号2:IgG結合ペプチド、H6
配列番号3:IgG結合ペプチド、H3
配列番号4:IgG結合ペプチド、D5
配列番号5:IgG結合ペプチド、E7
配列番号6:IgG結合ペプチド、sC12
配列番号7:IgG結合ペプチド、G3
配列番号8:IgG結合ペプチド、G11
配列番号9:IgG結合ペプチド、sA7
配列番号10:IgG結合ペプチド
配列番号11:IgG結合ペプチド、2A1
配列番号12:IgG結合ペプチド、2A4
配列番号13:IgG結合ペプチド、2F12
配列番号14:IgG結合ペプチド、2H1
配列番号15:IgG結合ペプチド、2F2
配列番号16:IgG結合ペプチド、2F4
配列番号17:IgG結合ペプチド、2F6
配列番号18:IgG結合ペプチド、2F7
配列番号19:IgG結合ペプチド、2F9
配列番号20:IgG結合ペプチド
配列番号21:IgG結合ペプチド、2A1Gly
配列番号22:IgG結合ペプチド、RSS
配列番号23:IgG結合ペプチド
配列番号24:IgG結合ペプチド、pep14
配列番号25:IgG結合ペプチド、pep11
配列番号26:IgG結合ペプチド、pep21
配列番号27:IgG結合ペプチド、pep24
配列番号28:IgG結合ペプチド、pep3
配列番号29:IgG結合ペプチド、pep9
配列番号30:IgG結合ペプチド、pep7
配列番号31:IgG結合ペプチド、pep25
配列番号32:IgG結合ペプチド、pep27
配列番号33:IgG結合ペプチド、pep31
配列番号34:IgG結合ペプチド、pep1
配列番号35:IgG結合ペプチド、pep2
配列番号36:IgG結合ペプチド、pep3
配列番号37:IgG結合ペプチド、pep4
配列番号38:IgG結合ペプチド、pep5
配列番号39:IgG結合ペプチド、pep6
配列番号40:IgG結合ペプチド、pep10
配列番号41:IgG結合ペプチド、pep12
配列番号42:IgG結合ペプチド、pep29
配列番号43:IgG結合ペプチド、pep15
配列番号44:IgG結合ペプチド、pep16
配列番号45:IgG結合ペプチド、pep17
配列番号46:IgG結合ペプチド、pep18
配列番号47:IgG結合ペプチド、pep19
配列番号48:IgG結合ペプチド、pep20
配列番号49:IgG結合ペプチド、pep22
配列番号50:IgG結合ペプチド、pep23
配列番号51:IgG結合ペプチド、pep26
配列番号52:IgG結合ペプチド、pep28
配列番号53:IgG結合ペプチド、pep29
配列番号54:IgG結合ペプチド、pep30
配列番号55:IgG結合ペプチド、pep11_2
配列番号56:IgG結合ペプチド
配列番号57:IgG結合ペプチド、p17
配列番号58:IgG結合ペプチド、p6
配列番号59:IgG結合ペプチド、p12
配列番号60:IgG結合ペプチド、p16
配列番号61:IgG結合ペプチド、p19
配列番号62:IgG結合ペプチド、p36
配列番号63:IgG結合ペプチド、p2_2
配列番号64:IgG結合ペプチド、p4
配列番号65:IgG結合ペプチド、p5
配列番号66:IgG結合ペプチド、p13
配列番号67:IgG結合ペプチド、p14
配列番号68:IgG結合ペプチド、p15_2
配列番号69:IgG結合ペプチド、p20
配列番号70:IgG結合ペプチド、p26
配列番号71:IgG結合ペプチド、p27
配列番号72:IgG結合ペプチド、p28
配列番号73:IgG結合ペプチド
配列番号74:IgG結合ペプチド、p2
配列番号75:IgG結合ペプチド、p15
配列番号76:IgG結合ペプチド、p24
配列番号77:IgG結合ペプチド、p25
配列番号78:IgG結合ペプチド、p34
配列番号79:IgG結合ペプチド、p24_2
配列番号80:IgG結合ペプチド、p25_2
配列番号81:IgG結合ペプチド、p31
配列番号82:チオレドキシン融合タンパク質、H6_trx
配列番号83:チオレドキシン融合タンパク質、2A1_trx
配列番号84:チオレドキシン融合タンパク質、2A4_trx
配列番号85:チオレドキシン融合タンパク質、2F12_trx
配列番号86:チオレドキシン融合タンパク質、p17_trx
配列番号87:チオレドキシン融合タンパク質、pep14_trx
配列番号88:チオレドキシン融合タンパク質、pep21_trx
配列番号89:チオレドキシン融合タンパク質、pep24_trx
配列番号90:チオレドキシン融合タンパク質、pep3_trx
配列番号91:チオレドキシン融合タンパク質、pep9_trx
配列番号92:チオレドキシン融合タンパク質、pep7_trx
配列番号93:チオレドキシン融合タンパク質、pep25_trx
配列番号94:チオレドキシン融合タンパク質、pep27_trx
配列番号95:チオレドキシン融合タンパク質、pep31_trx
配列番号96:チオレドキシン融合タンパク質
配列番号97:チオレドキシン融合タンパク質、p2_trx
配列番号98:チオレドキシン融合タンパク質、p6_trx
配列番号99:チオレドキシン融合タンパク質、p12_trx
配列番号100:チオレドキシン融合タンパク質、p15_trx
配列番号101:チオレドキシン融合タンパク質、p16_trx
配列番号102:チオレドキシン融合タンパク質、p19_trx
配列番号103:チオレドキシン融合タンパク質、p24_trx
配列番号104:チオレドキシン融合タンパク質、p25_trx
配列番号105:チオレドキシン融合タンパク質、p34_trx
配列番号106:チオレドキシン融合タンパク質、p36_trx
配列番号107:チオレドキシン融合タンパク質、p2_2_trx
配列番号108:チオレドキシン融合タンパク質、p4_trx
配列番号109:チオレドキシン融合タンパク質、p5_trx
配列番号110:チオレドキシン融合タンパク質、p13_trx
配列番号111:チオレドキシン融合タンパク質、p14_trx
配列番号112:チオレドキシン融合タンパク質、p15_2_trx
配列番号113:チオレドキシン融合タンパク質、p20_trx
配列番号114:チオレドキシン融合タンパク質、p24_2_trx
配列番号115:チオレドキシン融合タンパク質、p25_2_trx
配列番号116:チオレドキシン融合タンパク質、p26_trx
配列番号117:チオレドキシン融合タンパク質、p27_trx
配列番号118:チオレドキシン融合タンパク質、p28_trx
配列番号119:チオレドキシン融合タンパク質、p31_trx
配列番号120:オリゴDNA
配列番号121:オリゴDNA
配列番号122:オリゴDNA
配列番号123:オリゴDNA
配列番号124:オリゴDNA
配列番号125:オリゴDNA
配列番号126:オリゴDNA
配列番号127:オリゴDNA
配列番号128:オリゴDNA
配列番号129:オリゴDNA
配列番号130:オリゴDNA
配列番号131:オリゴDNA
配列番号132:オリゴDNA
配列番号133:オリゴDNA
配列番号134:オリゴDNA
配列番号135:オリゴDNA
配列番号136:オリゴDNA
配列番号137:オリゴDNA
配列番号138:オリゴDNA
配列番号139:オリゴDNA
配列番号140:オリゴDNA
配列番号141:オリゴDNA
配列番号142:オリゴDNA
配列番号143:オリゴDNA
配列番号144:オリゴDNA
配列番号145:オリゴDNA
配列番号146:オリゴDNA
配列番号147:オリゴDNA
配列番号148:オリゴDNA
配列番号149:オリゴDNA
配列番号150:オリゴDNA
配列番号151:オリゴDNA
配列番号152:オリゴDNA
配列番号153:オリゴDNA
配列番号154:オリゴDNA
配列番号155:オリゴDNA
配列番号156:オリゴDNA
配列番号157:オリゴDNA
配列番号158:IgG結合ペプチド、2A1_Q5R
配列番号159:IgG結合ペプチド、2A1_W6A
配列番号160:IgG結合ペプチド、2A1_S7A
配列番号161:IgG結合ペプチド、2A1_R17A
配列番号162:IgG結合ペプチド、2A1_S18A
配列番号163:IgG結合ペプチド、2A1_S19A
配列番号164:IgG結合ペプチド、2A1_I20A
配列番号165:IgG結合ペプチド、Fc-III
配列番号166:IgG結合ペプチド
配列番号167:IgG結合ペプチド
配列番号168:IgG結合ペプチドライブラリ
配列番号169:グリシンリンカー
配列番号170:IgG結合ペプチドライブラリ
配列番号171:IgG結合ペプチドライブラリ
配列番号172:IgG結合ペプチドライブラリ
配列番号173:IgG結合ペプチドライブラリ
配列番号174:IgG結合ペプチド、p17_P46A
配列番号175:IgG結合ペプチド、p17_D47A
配列番号176:IgG結合ペプチド、p17_W48A
配列番号177:IgG結合ペプチド、p17_R50A
配列番号178:IgG結合ペプチド、p17_M51A
配列番号179:オリゴDNA
配列番号180:オリゴDNA
配列番号181:オリゴDNA
配列番号182:オリゴDNA
配列番号183:オリゴDNA
Claims (37)
- 下記式1:
Y-D-P-x-T-G-T-W-R-S-x-[IL] (配列番号1) (1)
(式中、xは任意のアミノ酸残基を表す。 [ ]は[ ]内のアミノ酸残基のいずれか一つを表す。)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。 - 配列番号2~6:
YDPRTGTWRSSIAYGGG (配列番号2)
YDPGTGTWRSYLRFGGG (配列番号3)
YDPYTGTWRSSIWVLSG (配列番号4)
YDPGTGTWRSWLSFNVG (配列番号5)
YDPWTGTWRSFIWGGGG (配列番号6)
のいずれかで表されるアミノ酸配列からなる、請求項1に記載のポリペプチド。 - 配列番号2~6のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。
- 配列番号7~9:
YDPRTGTWLLYASRLLG (配列番号7)
YDPVTGTWTSSIASWMG (配列番号8)
YDPRTGTWRRSSLSYSG (配列番号9)
のいずれかで表されるアミノ酸配列からなる、請求項3に記載のポリペプチド。 - 下記式2:
R-[QRS]-x-x-[GS]-Y-D-P-R-T-G-T-W-R-S-S-I-A-Y-G-G (配列番号10) (2)
(式中、xは任意のアミノ酸残基を表す。[ ]は[ ]内のアミノ酸残基のいずれか一つを表す。)で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。 - 配列番号11~14:
GVVRQWSGYDPRTGTWRSSIAYGGG (配列番号11)
AGSRRAHGYDPRTGTWRSSIAYGGG (配列番号12)
ASVRSWSSYDPRTGTWRSSIAYGGG (配列番号13)
SWRRRGSSYDPRTGTWRSSIAYGGG (配列番号14)
のいずれかで表されるアミノ酸配列からなる、請求項5に記載のポリペプチド。 - 配列番号11~14のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。
- 配列番号15~19、及び158~164:
TGRGRSARYDPRTGTWRSSIAYGGG (配列番号15)
HWVNGRSGYDPRTGTWRSSIAYGGG (配列番号16)
ERWITWSGYDPRTGTWRSSIAYGGG (配列番号17)
GSVVRWRGYDPRTGTWRSSIAYGGG (配列番号18)
GAVYRRSFYDPRTGTWRSSIAYRGG (配列番号19)
GVVRRWSGYDPRTGTWRSSIAYGGG (配列番号158)
GVVRQAQSGYDPRTGTWRSSIAYGGG (配列番号159)
GVVRQWAGYDPRTGTWRSSIAYGGG (配列番号160)
GVVRQWSGYDPRTGTWASSIAYGGG (配列番号161)
GVVRQWSGYDPRTGTWRASIAYGGG (配列番号162)
GVVRQWSGYDPRTGTWRSAIAYGGG (配列番号163)
GVVRQWSGYDPRTGTWRSSAAYGGG (配列番号164)
のいずれかで表されるアミノ酸配列からなる、請求項7に記載のポリペプチド。 - 下記式3:
G-V-V-R-Q-W-S-G-x-x-x-x-x-x-x-x-R-S-S-I-A-Y-G-G (配列番号20) (3)
(式中、xは任意のアミノ酸残基を表す)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。 - 配列番号21:
GVVRQWSGGGGSGGGGRSSIAYGGG (配列番号21)
で表されるアミノ酸配列からなる、請求項9に記載のポリペプチド。 - 配列番号22:
RSSIAYGGG (配列番号22)
で表されるアミノ酸配列からなる、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。 - 下記式4:
D-A-A-W-H-L-G-E-L-V-W-A-T-Y-Y-D-P-E-T-G-T-W-x-P-D-W-x-x-M
(配列番号23) (4)
(式中、xは任意のアミノ酸残基を表す)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。 - 配列番号24~54:
DAAWHLGELVWATYYDPETGTWQPDWLYMTTR (配列番号24)
DAAWHLGELVWATYYDPETGTWAPDWRLMQGQ (配列番号25)
DAAWHLGELVWATYYDPETGTWLPDWQTMAQK (配列番号26)
DAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号27)
DAAWHLGELVWATYYDPETGTWQPDWRAMSGR (配列番号28)
DAAWHLGELVWATYYDPETGTWRPDWKWMSTH (配列番号29)
DAAWHLGELVWATYYDPETGTWEPDWKLMQRP (配列番号30)
DAAWHLGELVWATYYDPETGTWQPDWDIMAGH (配列番号31)
DAAWHLGELVWATYYDPETGTWLPDWDVMVRQ (配列番号32)
DAAWHLGELVWATYYDPETGTWVPDWERMKQH (配列番号33)
DAAWHLGELVWATYYDPETGTWEPDWSKMRPQ (配列番号34)
DAAWHLGELVWATYYDPETGTWRPDWAVMATP (配列番号35)
DAAWHLGELVWATYYDPETGTWKPDWRMMGVP (配列番号36)
DAAWHLGELVWATYYDPETGTWLPDWDYMSSK (配列番号37)
DAAWHLGELVWATYYDPETGTWMPDWDRMLRR (配列番号38)
DAAWHLGELVWATYYDPETGTWTPDWNAMSQR (配列番号39)
DAAWHLGELVWATYYDPETGTWQPDWKRMTSR (配列番号40)
DAAWHLGELVWATYYDPETGTWQPDWGRMNSK (配列番号41)
DAAWHLGELVWATYYDPETGTWAPDWNRMRDFNRSFREV (配列番号42)
DAAWHLGELVWATYYDPETGTWVPDWDAMSSR (配列番号43)
DAAWHLGELVWATYYDPETGTWIPDWTRMQTW (配列番号44)
DAAWHLGELVWATYYDPETGTWKPDWQRMKLH (配列番号45)
DAAWHLGELVWATYYDPETGTWLPDWSQMRPQ (配列番号46)
DAAWHLGELVWATYYDPETGTWLPDWDTMTPR (配列番号47)
DAAWHLGELVWATYYDPETGTWQPDWSVMKSL (配列番号48)
DAAWHLGELVWATYYDPETGTWVPDWDTMHAAINRSFREV (配列番号49)
DAAWHLGELVWATYYDPETGTWIPDWRAMSQF (配列番号50)
DAAWHLGELVWATYYDPETGTWLPDWNLMGQH (配列番号51)
DAAWHLGELVWATYYDPETGTWRPDWARMEPM (配列番号52)
DAAWHLGELVWATYYDPETGTWKPDWQVMSPVSNRSFREV (配列番号53)
DAAWHLGELVWATYYDPETGTWQPDWEIMRPF (配列番号54)
のいずれかで表されるアミノ酸配列からなる、請求項12に記載のポリペプチド。 - 配列番号24~54のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。
- 配列番号55:
EAWHLGELVWATYYDPETGTWRPDWSRMSGR (配列番号55)
で表されるアミノ酸配列からなる、請求項14に記載のポリペプチド。 - 下記式5:
[RSG]-[AGV]-x-Y-D-P-E-T-G-T-W-Y-D-A-A-W-H-L-G-E-L-V-W-A-T-Y-Y-D-P-E-T-G-T-W-E-P-D-W-Q-R-M-L-G-Q (配列番号56) (5)
(式中、xは任意のアミノ酸残基を表す。[ ]は[ ]内のアミノ酸残基のいずれか一つを表す。)
で示されるアミノ酸配列からなるポリペプチドであるか、あるいは該アミノ酸配列において1個若しくは数個のアミノ酸残基が付加されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。 - 配列番号57~72:
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号57)
VISLGSDRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号58)
IMSVDGSSARYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号59)
VDLRAHGGAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号60)
WSRFSSRSVAYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号61)
GNPSDSASAWYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号62)
SNFVRSPSAWYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号63)
IPYGFPGRGEYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号64)
GPYNIPDSAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号65)
WPLNAPSSAFYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号66)
VPPRFSSSAQYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号67)
FLVGLHAGAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号68)
VVRVDHSSAVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号69)
WMEFYPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号70)
DGVGPGSRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号71)
FVSSLPNSAMYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号72)
のいずれかで表されるアミノ酸配列からなる、請求項16に記載のポリペプチド。 - 配列番号57~72のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸残基が、付加、削除、置換又は挿入されたアミノ酸配列からなるポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。
- 配列番号73~81、及び174~178:
GRAFSGSRRWYDPETGTWYDAAWHLGELVWATYYDPETGTWAPDWRLMQGQ (配列番号73)
VMATEVVRGVYDPETGTWYDATWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号74)
MMVRPPRLGVYDPEPGTWYDATWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号75)
ERHLVSDYLHYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号76)
FSDLDSFGVSYDPETGTWYDAAWHRGELVWATYYDPETGTWEPDWQRMLGQ (配列番号77)
LFDNKLKHASYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号78)
GSCKFSSSCHYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号79)
LIPPGGISPWYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRMLGQ (配列番号80)
LNDFLTPTAWYDPETGTWYDAAWHLGELVWATYYDPETGTWLPDWQTMAQK (配列番号81)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEADWQRMLGQ (配列番号174)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPAWQRMLGQ (配列番号175)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDAQRMLGQ (配列番号176)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQAMLGQ (配列番号177)
GPGISAFSPGRGVYDPETGTWYDAAWHLGELVWATYYDPETGTWEPDWQRALGQ (配列番号178)
のいずれかで表されるアミノ酸配列からなる、請求項18に記載のポリペプチド。 - 請求項1、3、5、7、9、12、14、16、及び18のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端に第2のポリペプチドを伸張した連結型ポリペプチドであって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド。
- 配列番号2~9、11~19、21、22、24~55、57~81、158~164、及び174~178のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端に第2のポリペプチドを伸張した連結型ポリペプチドであることを特徴とする、請求項20に記載のポリペプチド。
- 請求項1、3、5、7、9、12、14、16、及び18のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端にタンパク質を結合した融合タンパク質であって、免疫グロブリンGのFc領域に対する結合活性を示すタンパク質。
- 配列番号2~9、11~19、21、22、24~55、57~81、158~164、及び174~178のいずれかのポリペプチドのアミノ末端あるいはカルボキシル末端あるいは両末端にタンパク質を結合した融合タンパク質であることを特徴とする、請求項22に記載のタンパク質。
- 配列番号82~119のいずれかで表されるアミノ酸配列からなる、請求項22に記載のタンパク質。
- 請求項1~24のいずれかに記載のポリペプチドあるいはタンパク質をコードする核酸。
- 配列番号120~157、及び179~183のいずれかで表される塩基配列からなる、請求項25に記載の核酸。
- 請求項25又は26に記載の核酸を含有する組換えベクター。
- 請求項27に記載の組換えベクターが導入された形質転換体。
- 請求項25又は26に記載の核酸を含有する組換えファージ又は組換えウイルス。
- 請求項1、3、5、7、9、12、14、16、及び18のポリペプチド、請求項20の連結型ポリペプチド、並びに請求項22の融合タンパク質のいずれかに有機化合物あるいは無機化合物あるいは有機化合物と無機化合物の両方が結合した修飾ポリペプチド又は修飾タンパク質であって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド又はタンパク質。
- 配列番号2~9、11~19、21、22、24~55、57~81、158~164、及び174~178のポリペプチド、並びに配列番号82~119の融合タンパク質のいずれかに有機化合物あるいは無機化合物あるいは有機化合物と無機化合物の両方が結合した修飾ポリペプチド又は修飾タンパク質であって、免疫グロブリンGのFc領域に対する結合活性を示すポリペプチド又はタンパク質。
- 請求項1~21のいずれかに記載のポリペプチド、請求項22~24のいずれかに記載のタンパク質、又は請求項30~31のいずれかに記載のポリペプチド若しくはタンパク質が、水不溶性の固相支持体に固定化されていることを特徴とする、固定化ポリペプチド又は固定化タンパク質。
- 請求項1~21のいずれかに記載のポリペプチド、請求項22~24のいずれかに記載のタンパク質、請求項25~26のいずれかに記載の核酸、請求項27に記載の組換えベクター、請求項28に記載の形質転換体、請求項29に記載の組換えファージ又は組換えウイルス、請求項30~31のいずれかに記載のポリペプチド又はタンパク質、及び請求項32に記載の固定化ポリペプチド又は固定化タンパク質からなる群より選択される少なくとも1つを含む、抗体、免疫グロブリンGあるいは免疫グロブリンGのFc領域を含有するタンパク質を検出、精製、固定化又は除去するためのキット。
- 被検試料中の非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を検出するための方法であって、
(1) 被検試料を、請求項1~21のいずれかに記載のポリペプチド、請求項22~24のいずれかに記載のタンパク質、請求項28に記載の形質転換体、請求項29に記載の組換えファージ若しくは組換えウイルス、請求項30~31のいずれかに記載のポリペプチド若しくはタンパク質、又は請求項32に記載の固定化ポリペプチド若しくは固定化タンパク質と接触させる工程、及び
(2) 被検試料と、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質との間で結合が生じたか否かを判定する工程、
を含む方法。 - 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を精製するための方法であって、
(1) 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を含む試料を請求項1~21のいずれかに記載のポリペプチド、請求項22~24のいずれかに記載のタンパク質、請求項28に記載の形質転換体、請求項29に記載の組換えファージ若しくは組換えウイルス、請求項30~31のいずれかに記載のポリペプチド若しくはタンパク質、又は請求項32に記載の固定化ポリペプチド若しくは固定化タンパク質と接触させて、非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合させる工程、及び
(2) ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合した非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を試料から回収する工程、
を含む方法。 - 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を除去するための方法であって、
(1) 非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を含む試料を請求項1~21のいずれかに記載のポリペプチド、請求項22~24のいずれかに記載のタンパク質、請求項28に記載の形質転換体、請求項29に記載の組換えファージ若しくは組換えウイルス、請求項30~31のいずれかに記載のポリペプチド若しくはタンパク質、又は請求項32に記載の固定化ポリペプチド若しくは固定化タンパク質と接触させて、非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を、ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合させる工程、及び
(2) ポリペプチド、タンパク質、形質転換体、組換えファージ若しくは組換えウイルス、又は固定化ポリペプチド若しくは固定化タンパク質と結合した非天然型立体構造を有する抗体、免疫グロブリンGあるいはFc領域含有タンパク質を試料から除去する工程、
を含む方法。 - 還元的環境下において実施される、請求項34~36のいずれかに記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/763,589 US9605029B2 (en) | 2013-01-28 | 2013-12-25 | Antibody-binding peptide |
JP2014558300A JP6363022B2 (ja) | 2013-01-28 | 2013-12-25 | 抗体結合性ペプチド |
EP13873013.0A EP2949750B1 (en) | 2013-01-28 | 2013-12-25 | Antibody-binding peptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-013217 | 2013-01-28 | ||
JP2013013217 | 2013-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014115229A1 true WO2014115229A1 (ja) | 2014-07-31 |
Family
ID=51227046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/007583 WO2014115229A1 (ja) | 2013-01-28 | 2013-12-25 | 抗体結合性ペプチド |
Country Status (4)
Country | Link |
---|---|
US (1) | US9605029B2 (ja) |
EP (1) | EP2949750B1 (ja) |
JP (1) | JP6363022B2 (ja) |
WO (1) | WO2014115229A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017187476A (ja) * | 2016-03-31 | 2017-10-12 | 東ソー株式会社 | 変性抗体測定方法 |
JP2017184730A (ja) * | 2016-03-31 | 2017-10-12 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
WO2018043629A1 (ja) * | 2016-09-01 | 2018-03-08 | 国立研究開発法人産業技術総合研究所 | 非天然型立体構造を形成した抗体に親和性を示すポリペプチド |
JP2018128408A (ja) * | 2017-02-10 | 2018-08-16 | 東ソー株式会社 | 抗体凝集体形成予測方法 |
JP2018531284A (ja) * | 2015-09-25 | 2018-10-25 | ニューロナックス | 環状ポリペプチド、それらを得る方法、及びその治療的使用 |
JP2019504004A (ja) * | 2015-12-16 | 2019-02-14 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクRuprecht−Karls−Universitaet Heidelberg | 環状ntcp標的化ペプチドおよび侵入阻害剤としてのその使用 |
JP2019109134A (ja) * | 2017-12-19 | 2019-07-04 | 東ソー株式会社 | ゲル濾過クロマトグラフィを用いた抗体の変性度合評価方法 |
JP2019147787A (ja) * | 2017-11-09 | 2019-09-05 | 国立研究開発法人産業技術総合研究所 | ポリペプチドの凝集化抑制方法 |
WO2019172401A1 (ja) * | 2018-03-09 | 2019-09-12 | 国立研究開発法人産業技術総合研究所 | 変性抗体を模倣するポリペプチド |
WO2020027237A1 (ja) * | 2018-08-01 | 2020-02-06 | 国立大学法人鹿児島大学 | ペプチド融合タンパク質 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3489396B1 (en) * | 2012-12-27 | 2021-03-03 | National Institute of Advanced Industrial Science and Technology | Molecule library constructed on the basis of backbone structure of microprotein |
US11691143B2 (en) * | 2017-12-15 | 2023-07-04 | Creoptix Ag | Assemblies and methods for screening sample fluids |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
JP2004187563A (ja) | 2002-12-10 | 2004-07-08 | Peptide Door Co Ltd | IgGに結合性を有するペプチド又は該ペプチドを表面に呈示したファージを用いたIgGの検出方法 |
WO2008054030A1 (en) | 2006-11-02 | 2008-05-08 | Kagoshima University | IgG-BINDING PEPTIDE |
JP2009112282A (ja) * | 2007-11-09 | 2009-05-28 | National Institute Of Advanced Industrial & Technology | 極微小タンパク質およびその結晶 |
JP2013013217A (ja) | 2011-06-29 | 2013-01-17 | Fuji Electric Co Ltd | 無効電力補償装置の補償効果検証装置 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
EP3489396B1 (en) * | 2012-12-27 | 2021-03-03 | National Institute of Advanced Industrial Science and Technology | Molecule library constructed on the basis of backbone structure of microprotein |
-
2013
- 2013-12-25 EP EP13873013.0A patent/EP2949750B1/en active Active
- 2013-12-25 US US14/763,589 patent/US9605029B2/en active Active
- 2013-12-25 JP JP2014558300A patent/JP6363022B2/ja active Active
- 2013-12-25 WO PCT/JP2013/007583 patent/WO2014115229A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
JP2004187563A (ja) | 2002-12-10 | 2004-07-08 | Peptide Door Co Ltd | IgGに結合性を有するペプチド又は該ペプチドを表面に呈示したファージを用いたIgGの検出方法 |
WO2008054030A1 (en) | 2006-11-02 | 2008-05-08 | Kagoshima University | IgG-BINDING PEPTIDE |
JP2009112282A (ja) * | 2007-11-09 | 2009-05-28 | National Institute Of Advanced Industrial & Technology | 極微小タンパク質およびその結晶 |
JP2013013217A (ja) | 2011-06-29 | 2013-01-17 | Fuji Electric Co Ltd | 無効電力補償装置の補償効果検証装置 |
Non-Patent Citations (38)
Title |
---|
"Folding of Protein", SPRINGER-VERLAG GMBH |
"Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates", 2010, BUSINESS INSIGHTS LTD., pages: 16 - 20 |
BASLE E; JOUBERT N; PUCHEAULT M: "Protein chemical modification on endogenous amino acids", CHEM BIOL., vol. 17, no. 3, 2010, pages 213 - 27, XP026984435 |
BERKOWITZ SA; ENGEN JR; MAZZEO JR; JONES GB.: "Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.", NAT REV DRUG DISCOV., vol. 11, no. 7, 2012, pages 527 - 540 |
BRAISTED AC; WELLS JA: "Minimizing a binding domain from protein A", PROC NATL ACAD SCI USA., vol. 93, no. 12, 1996, pages 5688 - 5692, XP002555464, DOI: doi:10.1073/pnas.93.12.5688 |
BRUNGER AT; ADAMS PD; CLORE GM; DELANO WL; GROS P; GROSSE-KUNSTLEVE RW; JIANG JS; KUSZEWSKI J; NILGES M; PANNU NS: "Crystallography & NMR system: A new software suite for macromolecular structure determination", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 54, 1998, pages 905 - 921 |
BRYMORA A; VALOVA VA; ROBINSON PJ.: "Protein-protein interactions identified by pull-down experiments and mass spectrometry", CURR PROTOC CELL BIOL., 2004 |
BUCHNER J; RENNER M; LILIE H; HINZ HJ; JAENICKE R; KIEFHABEL T; RUDOLPH R.: "Alternatively folded states of an immunoglobulin", BIOCHEMISTRY, vol. 30, no. 28, 1991, pages 6922 - 6929 |
DELANO WL; ULTSCH MH; DE VOS AM; WELLS JA: "Convergent solutions to binding at a protein-protein interface", SCIENCE, vol. 287, no. 5456, 2000, pages 1279 - 1283, XP002211313, DOI: doi:10.1126/science.287.5456.1279 |
DIAS RL; FASAN R; MOEHLE K; RENARD A; OBRECHT D; ROBINSON JA.: "Protein ligand design: from phage display to synthetic protein epitope mimetics in human antibody Fc-binding peptidomimetics", J AM CHEM SOC., vol. 128, no. 8, 2006, pages 2726 - 2732, XP008109926, DOI: doi:10.1021/ja057513w |
DIAS, R. L. A. ET AL.: "Protein Ligand Design: From Phage Display to Synthetic Protein Epitope Mimetics in Human Antibody Fc-Binding Peptidomimetics", JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 128, 2006, pages 2726 - 2732, XP008109926 * |
EHRLICH GK; BAILON P.: "Identification of peptides that bind to the constant region of a humanized IgG1 monoclonal antibody using phage display", J MOL RECOGNIT, vol. 11, no. 1-6, 1998, pages 121 - 125, XP009055200, DOI: doi:10.1002/(SICI)1099-1352(199812)11:1/6<121::AID-JMR406>3.0.CO;2-Z |
EMSLEY P; COWTAN K.: "Coot: model-building tools for molecular graphics", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR., vol. 60, 2004, pages 2126 - 2132 |
FASSINA G; VERDOLIVA A, PALOMBO G; RUVO M; CASSANI G.: "Immunoglobulin specificity of TG19318: a novel synthetic ligand for antibody affinity purification", J MOL RECOGNIT., vol. 11, no. 1-6, 1998, pages 128 - 133 |
FASSINA G; VERDOLIVA A; ODIERNA MR; RUVO M; CASSINI G: "Protein A mimetic peptide ligand for affinity purification of antibodies", J MOL. RECOGNIT., vol. 9, no. 5-6, 1996, pages 564 - 569 |
FEIGE MJ; SIMPSON ER; HEROLD EM; BEPPERLING A; HEGER K; BUCHNER J.: "Dissecting the alternatively folded state of the antibody Fab fragment", J. MOL. BIOL., vol. 399, no. 5, 2010, pages 719 - 730, XP027086452, DOI: doi:10.1016/j.jmb.2010.04.032 |
HIDEKI WATANABE ET AL.: "Bisho Tanpakushitsu o Kozo Kosei Yoso to shita Kogata Jinko Tanpakushitsu Sekkei", DAI 13 KAI PROTEIN SCIENCE SOCIETY OF JAPAN NENKAI PROGRAM YOSHISHU, 31 May 2013 (2013-05-31), XP008179699 * |
HOBER S; NORD K; LINHULT M: "Protein A chromatography for antibody purification", J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI., vol. 848, no. 1, 2007, pages 40 - 47, XP002560075, DOI: doi:10.1016/j.jchromb.2006.09.030 |
JOUBERT MK; HOKOM M; EAKIN C; ZHOU L; DESHPANDE M; BAKER MP; GOLETZ TJ; KERWIN BA; CHIRMULE N; NARHI LO: "Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses", J. BIOL. CHEM., vol. 287, no. 30, 2012, pages 25266 - 25279 |
KANMERT D; BRORSSON AC; JONSSON BH; ENANDER K: "Thermal induction of an alternatively folded state in human IgG-Fc", HEMISTRY, vol. 50, no. 6, 2011, pages 981 - 988 |
KANNO S; YANAGIDA Y; HARUYAMA T; KOBATAKE E; AIZAWA M.: "Assembling of engineered IgG-binding protein on gold surface for highly oriented antibody immobilization", J BIOTECHNOL., vol. 76, no. 2-3, 2000, pages 207 - 214, XP002651277, DOI: doi:10.1016/s0168-1656(99)00186-8 |
KROOK M; MOSBACH K; RAMSTROM O.: "Novel peptides binding to the Fc-portion of immunoglobulins obtained from a combinatorial phage display peptide library", J IMMUNOL METHODS, vol. 221, no. 1-2, 1998, pages 151 - 157, XP004153568, DOI: doi:10.1016/S0022-1759(98)00177-X |
KROOK, M. ET AL.: "Novel peptides binding to the Fc-portion of immunoglobulins obtained from a combinatorial phage display peptide library", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 221, 1998, pages 151 - 157, XP004153568 * |
LUO Q; JOUBERT MK; STEVENSON R; KETCHEM RR; NARHI LO; WYPYCH J.: "Chemical modifications in therapeutic protein aggregates generated under different stress conditions", J. BIOL. CHEM., vol. 286, no. 28, 2011, pages 25134 - 25144 |
PARK SH; RAINES RT: "Fluorescence polarization assay to quantify protein-protein interactions", METHODS MOL BIOL., vol. 261, 2004, pages 161 - 166 |
ROSENBERG AS.: "Effects of protein aggregates an immunologic perspective", AAPS J., vol. 8, no. 3, 2006, pages E501 - 507, XP003021154, DOI: doi:10.1208/aapsj080359 |
SAKAMOTO K; ITO Y; HATANAKA T; SONI PB; MORI T; SUGIMURA K.: "Discovery and characterization of a peptide motif that specifically recognizes a non-native conformation of human IgG induced by acidic pH conditions", J BIOL CHEM., vol. 284, no. 15, 2009, pages 9986 - 9993, XP002547442, DOI: doi:10.1074/jbc.M807618200 |
See also references of EP2949750A4 |
SHINYA HONDA ET AL.: "Development and Market of Antibody Drug", 2012, CMC PUBLISHING CO., LTD |
SHINYA HONDA: "Purification Process of Antibody Drug - Protein A Affinity Chromatography", CMC STUDY/APPLICATION AND ACQUISITION OF EQUIVALENCY IN BIO/ANTIBODY DRUG/GENERIC DRUG, 2011, pages 149 - 172 |
TAIRO OSHIMA; KOICHI SUZUKI; YOSHIAKI FUJII; TAKASHI MURAMATSU: "Post Sequence Protein Experimental Method", vol. 3, TOKYO KAGAKU DOJIN |
THIES MJ; KAMMERMEIER R; RICHTER K; BUCHNER J.: "The alternatively folded state of the antibody C(H)3 domain", J. MOL. BIOL., vol. 309, no. 5, 2001, pages 1077 - 1085, XP004479201, DOI: doi:10.1006/jmbi.2001.4707 |
VERDOLIVA A; MARASCO D; DE CAPUA A; SAPORITO A; BELLOFIORE P; MANFREDI V; FATTORUSSO R; PEDONE C; RUVO M.: "A new ligand for immunoglobulin g subdomains by screening of a synthetic peptide library", CHEMBIOCHEM, vol. 6, no. 7, 2005, pages 1242 - 1253 |
WATANABE H; MATSUMARU H; OOISHI A; FENG Y; ODAHARA T; SUTO K; HONDA S.: "Optimizing pH response of affinity between protein G and IgG Fc: how electrostatic modulations affect protein-protein interactions", J BIOL CHEM., vol. 284, no. 18, 2009, pages 12373 - 12383, XP055105971, DOI: doi:10.1074/jbc.M809236200 |
WATANABE, H. ET AL.: "Tracing primordial protein evolution through structurally guided stepwise segment elongation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 6, 19 December 2013 (2013-12-19), pages 3394 - 3404, XP055262180 * |
WINN MD; BALLARD CC; COWTAN KD; DODSON EJ; EMSLEY P; EVANS PR; KEEGAN RM; KRISSINEL EB; LESLIE AG; MCCOY A: "Overview of the CCP4 suite and current developments", ACTA CRYSTALLOGR D BIOL CRYSTALLOGR., vol. 67, 2011, pages 235 - 242 |
WITTIG I; SCHAGGER H.: "Native electrophoretic techniques to identify protein-protein interactions", PROTEOMICS, vol. 9, no. 23, 2009, pages 5214 - 23 |
YOSHITAKE S; YAMADA Y; ISHIKAWA E; MASSEYEFF R.: "Conjugation of glucose oxidase from Aspergillus niger and rabbit antibodies using N-hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)-maleimide", EUR. J. BIOCHEM., vol. 101, no. 2, 1979, pages 395 - 399 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6998878B2 (ja) | 2015-09-25 | 2022-01-18 | アクソルティス・ファーマ | 環状ポリペプチド、それらを得る方法、及びその治療的使用 |
JP2018531284A (ja) * | 2015-09-25 | 2018-10-25 | ニューロナックス | 環状ポリペプチド、それらを得る方法、及びその治療的使用 |
JP7362142B2 (ja) | 2015-12-16 | 2023-10-17 | ルプレヒト-カールス-ウニヴェルジテート ハイデルベルク | 環状ntcp標的化ペプチドおよび侵入阻害剤としてのその使用 |
US11401304B2 (en) | 2015-12-16 | 2022-08-02 | Ruprecht-Karls-Universität Heidelberg | Cyclic NTCP-targeting peptides and their uses as entry inhibitors |
JP2019504004A (ja) * | 2015-12-16 | 2019-02-14 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクRuprecht−Karls−Universitaet Heidelberg | 環状ntcp標的化ペプチドおよび侵入阻害剤としてのその使用 |
JP2022022455A (ja) * | 2015-12-16 | 2022-02-03 | ルプレヒト-カールス-ウニヴェルジテート ハイデルベルク | 環状ntcp標的化ペプチドおよび侵入阻害剤としてのその使用 |
JP2017184730A (ja) * | 2016-03-31 | 2017-10-12 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
JP2017187476A (ja) * | 2016-03-31 | 2017-10-12 | 東ソー株式会社 | 変性抗体測定方法 |
JP6992262B2 (ja) | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
JPWO2018043629A1 (ja) * | 2016-09-01 | 2019-06-24 | 国立研究開発法人産業技術総合研究所 | 非天然型立体構造を形成した抗体に親和性を示すポリペプチド |
WO2018043629A1 (ja) * | 2016-09-01 | 2018-03-08 | 国立研究開発法人産業技術総合研究所 | 非天然型立体構造を形成した抗体に親和性を示すポリペプチド |
US11008365B2 (en) | 2016-09-01 | 2021-05-18 | National Institute Of Advanced Industrial Science And Technology | Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure |
JP2018128408A (ja) * | 2017-02-10 | 2018-08-16 | 東ソー株式会社 | 抗体凝集体形成予測方法 |
JP2019147787A (ja) * | 2017-11-09 | 2019-09-05 | 国立研究開発法人産業技術総合研究所 | ポリペプチドの凝集化抑制方法 |
US10941179B2 (en) | 2017-11-09 | 2021-03-09 | National Institute Of Advanced Industrial Science And Technology | Method for suppressing aggregation of polypeptide |
JP7158015B2 (ja) | 2017-11-09 | 2022-10-21 | 国立研究開発法人産業技術総合研究所 | ポリペプチドの凝集化抑制方法 |
JP2019109134A (ja) * | 2017-12-19 | 2019-07-04 | 東ソー株式会社 | ゲル濾過クロマトグラフィを用いた抗体の変性度合評価方法 |
WO2019172401A1 (ja) * | 2018-03-09 | 2019-09-12 | 国立研究開発法人産業技術総合研究所 | 変性抗体を模倣するポリペプチド |
JP7115773B2 (ja) | 2018-03-09 | 2022-08-09 | 国立研究開発法人産業技術総合研究所 | 変性抗体を模倣するポリペプチド |
JPWO2019172401A1 (ja) * | 2018-03-09 | 2021-02-04 | 国立研究開発法人産業技術総合研究所 | 変性抗体を模倣するポリペプチド |
WO2020027237A1 (ja) * | 2018-08-01 | 2020-02-06 | 国立大学法人鹿児島大学 | ペプチド融合タンパク質 |
JPWO2020027237A1 (ja) * | 2018-08-01 | 2021-08-02 | 国立大学法人 鹿児島大学 | ペプチド融合タンパク質 |
CN112469736A (zh) * | 2018-08-01 | 2021-03-09 | 国立大学法人鹿儿岛大学 | 肽融合蛋白质 |
JP7202577B2 (ja) | 2018-08-01 | 2023-01-12 | 国立大学法人 鹿児島大学 | ペプチド融合タンパク質 |
US11643474B2 (en) | 2018-08-01 | 2023-05-09 | Kagoshima University | Peptide fusion protein |
Also Published As
Publication number | Publication date |
---|---|
US9605029B2 (en) | 2017-03-28 |
EP2949750A1 (en) | 2015-12-02 |
JPWO2014115229A1 (ja) | 2017-01-19 |
EP2949750B1 (en) | 2019-11-13 |
US20150353608A1 (en) | 2015-12-10 |
EP2949750A4 (en) | 2016-07-06 |
JP6363022B2 (ja) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6363022B2 (ja) | 抗体結合性ペプチド | |
JP6883529B2 (ja) | 融合タンパク質を合成するための方法および製品 | |
US7981632B2 (en) | Sequentially arranged streptavidin-binding modules as affinity tags | |
Burgess et al. | Advances in gentle immunoaffinity chromatography | |
JP5994068B2 (ja) | IgG結合性ペプチド及びそれによるIgGの検出および精製方法 | |
JP4953390B2 (ja) | IgG結合性ペプチド | |
JP5904565B2 (ja) | 微小タンパク質の骨格構造に基づく分子ライブラリ | |
US20150183820A1 (en) | Scavenger containing protein formed from tandem-type multimer of mutant extracellular domain of protein g | |
US20140221613A1 (en) | Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g | |
Morris et al. | Heparin-binding peptide as a novel affinity tag for purification of recombinant proteins | |
KR20210092203A (ko) | 면역글로불린의 fc 도메인에 대한 결합 친화도가 결여된 신규 삼중-나선 폴리펩티드 및 이의 용도 | |
Kruljec et al. | Development and characterization of peptide ligands of immunoglobulin G Fc region | |
US11008365B2 (en) | Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure | |
WO2013065343A1 (ja) | 非ペプチドヒンジ部含有フレキシブル抗体様分子 | |
Gautam et al. | Human pIgR mimetic peptidic ligand for affinity purification of IgM: Part I: Ligand design and binding mechanism | |
JPH09104699A (ja) | 血清アミロイドaを認識する抗体 | |
US20190161521A1 (en) | Antibody binding nanofibrils | |
WO1997006184A1 (fr) | Anticorps reconnaissant l'amyloide a serique | |
JP6245688B2 (ja) | IgY特異的結合ペプチド及びそれによるIgYの精製法 | |
Furukawa et al. | Purification Using Affinity Tag Technology | |
JP2020117467A (ja) | 非天然型立体構造を有する抗体に親和性を示すポリペプチド | |
JP2011037802A (ja) | オートタキシンの精製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13873013 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014558300 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14763589 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013873013 Country of ref document: EP |